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Abstract 
 
Background 
 
Alzheimer’s disease (AD), the commonest form of dementia, affects people in both industrialised and 
developing countries.  Risk factors for the development of AD include age, the presence of the Apolipoprotein 
ε4 allele, low vitamin B12 and folate levels, and elevated plasma homocysteine concentrations.  Most research 
involving the associations between these risk factors and AD have been conducted in Europe and North 
America.  We know little about AD and its risk factors in a low to middle income country like South Africa, 
where nutrition is poor and the background population ApoE ε4 allelic frequency is high. 
Objective 
In this prospective observational study, I wished to determine the relationships between plasma 
homocysteine, vitamin B12, folate, ApoE ε4 status and cognition in a sample of older persons from the greater 
Cape Town metropolitan area of the Western Cape region of South Africa. 
Methods 
Cognitively healthy controls and AD participants, diagnosed using NINCDS-ADRDA criteria, were recruited from 
the community.  The study had both cross-sectional and longitudinal components. Cross-sectionally, I related 
non-fasting plasma homocysteine concentrations, vitamin B12 levels, folate concentrations and the ApoE ε4 
genotype to scores from a battery of cognitive tests including the Mini Mental State Examination (MMSE), the 
Cambridge Cognitive Examination (CAMCOG) and the Learning Subscale score of the CAMCOG.  In the 
longitudinal analysis, I tested whether baseline plasma homocysteine concentrations related to cognitive 
decline one year after the initial assessment. 
Results 
One hundred and thirteen participants were recruited: 60 controls and 53 AD participants.  Plasma 
homocysteine levels increased with age (rs= 0.418, p<0.001) and were inversely related to cognitive scores in 
all participants. Homocysteine concentrations were inversely related to vitamin B12 and folate in all study 
participants (vitamin B12 rs= -0.47, p<0.001, folate rs=-0.33, p=0.001). Homocysteine was inversely related to 
cognition but, in a regression model, this relation was confounded by the effects of age and years of 
education.  Another regression model showed that vitamin B12 and age independently predicted cognitive 
scores.  There were more ApoE ε4 carriers in the AD group compared with controls and ε4 carrier status was 
significantly associated with AD.  The ApoE ε4 allele modified the relationship between homocysteine and 
cognition.  The association between homocysteine and cognition was strong in ApoE ε4 carriers (e.g. MMSE, 
rs=0.33, p=0.003), but absent in ε4 non-carriers.  High baseline homocysteine concentrations did not predict 
cognitive decline 1 year later. 
Conclusions 
These findings, the first from an African low to middle income country, are consistent with those from studies 
in industrialised countries.  Plasma homocysteine levels increased with age and were inversely related to 
vitamin B12 and folate.  The ApoE ε4 allele strengthened the association between homocysteine and cognition, 
probably through mechanisms that increase neuronal susceptibility to homocysteine toxicity.  My study 
supports the idea that homocysteine-lowering therapy can reduce the risk of developing AD or slow the 
progression of the disease. 
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Chapter One 
 
Introduction  
 
Studies in Europe and North America have shown that Alzheimer’s disease (AD) is a multi-factorial 
degenerative process. Many studies have provided evidence of several risk factors, and proposed 
multiple disease mechanisms associated with neurodegeneration. Randomised controlled trials, 
although few, have focused on the treatment of modifiable risk factors for disease: vascular risk 
factors, vitamin deficiencies and plasma homocysteine- lowering therapies.  
Vascular risk factors- hypertension, dyslipidaemia, diabetes, smoking and atrial fibrillation- are 
accepted risk factors for AD (de la Torre 2004). Plasma homocysteine, a risk factor for cardiovascular 
disease and stroke (McCully 1969; Boushey et al. 1995; Bots et al. 1999; Bostom et al. 1999), is also a 
risk factor for cognitive impairment and AD (Seshadri et al. 2002; Ravaglia et al. 2003). Elevated 
homocysteine levels are markers of vitamin B12 and folate deficiency (Jacobsen 1998) and deficiency 
of these nutrients (and resultant hyperhomocysteinaemia), has been associated with cognitive 
decline in the elderly (Goodwin et al. 1983). The Apolipoprotein E ε4 allele is associated with an 
increased risk of atherosclerosis and AD (Stritmatter et al. 1993; Mahley et al. 1995). The 
interrelationships and synergistic activity amongst the above risk factors are thought to either 
initiate or potentiate the dementing process in the majority of AD cases (van Norden et al. 2011). 
It South Africa it is estimated that there are at least 3.9 million persons over the age of 60 (Statistics 
SA 2011) and approximately 250 000 persons living with dementia (www.alzheimers.org.za). Most 
clinicians and researchers in academic medical centres in South Africa believe that dementia and 
Alzheimer’s disease are underdiagnosed and under-reported in South Africa. Our country focuses on 
primary health care needs, and often healthcare workers are usually not trained to look for 
symptoms of cognitive impairment and associated diseases. Furthermore, we live in a multi-cultural 
society where lack of awareness and/or social stigmata surrounding memory impairment are 
common.  The older population in lower and middle income countries is growing rapidly, and older 
persons are living even longer. The challenge of studying the epidemiology of dementias and related 
neurodegenerative disorders is considerable. These studies are expensive, time consuming and 
require large numbers of trained staff and field workers. Increased awareness and education about 
AD would allow for improved health care services and treatment. In the meantime, primary 
prevention should focus upon targets suggested by current evidence: risk factors for vascular 
disease, including hypertension, smoking, type II diabetes and hyperlipidaemia and nutritional 
deficiencies (ADI World Report 2009). 
Little is known about the extent of AD and its associated factors in a South African context. In the 
Western Cape, we do not know how many persons are affected with AD, but anecdotal evidence 
suggests that it is not an uncommon disease. Moreover, South Africa has a population with a large 
number of individuals of low socioeconomic status. Dietary deficiency, especially that of vitamin B 
and folate are probably more common compared with first world countries. 
15 
 
In my research project, I aimed to describe the relationships between plasma homocysteine, vitamin 
B12, folate and Alzheimer’s disease in a group of older persons in the Western Cape. I hypothesised 
that elevated levels of plasma homocysteine and decreased concentrations of vitamin B12 and folate 
are associated with normal ageing and cognitive impairment. Furthermore, because our native 
South African population has the highest ApoE ε4 allelic frequency in the world, I wished to 
determine whether carriers of this allele had a greater burden of disease compared with non-
carriers and whether the association between plasma homocysteine and cognitive function was 
modified by the ε4 allele.  
This study is clinically relevant since the above factors are potentially modifiable risk factors for 
disease. Modifiable risk factors justifies the early identification of disease. Early identification may 
prevent or delay the onset of new cases of disease, and slow disease progression in those with 
established AD. 
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Chapter Two 
 
Background and Literature review 
 
2.1) Definition of Dementia and neurocognitive disorders 
 
Dementia is a syndrome characterized by an acquired global impairment of memory and other 
cognitive functions sufficient to interfere with normal life. There are many causes of dementia 
including Alzheimer’s disease (AD) and cerebrovascular disorders, and most are progressive. 
 
2.2) Definition and history of Alzheimer’s disease 
 
Alois Alzheimer (Figure 2.1), a lecturer at the Munich University Hospital, and a co-worker Emil 
Kraepelin, reported on an unusual case study involving a “peculiar severe disease process of the 
cerebral cortex”(Alzheimer 1906).  Alzheimer’s disease (AD) may be defined as a chronic, progressive 
degenerative disease of the brain, with complex multi-factorial risk factors and associations. 
Figure 2.1: Alois Alzheimer 1909 
 
 
Archive for History of Psychiatry, Department of Psychiatry, University of Munich 
Hippius et al. 2003 
 
Progressive mental deterioration in old age has been recognized and described throughout history. 
However, it was not until 1906 that Alois Alzheimer identified a collection of brain cell abnormalities 
which formed the basis of the disease.  
AD refers to the clinico-pathological entity of the histological changes of neurofibrillary tangles and 
senile plaques in the brain in a patient with the clinical syndrome of dementia.  The disease affects 
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neurones in the brain resulting in cognitive abnormalities, most prominently, the loss of memory, 
altered thinking and a decline in language skills as well as behavioural changes (Carlesimo et al. 
1992). 
Over the last decade, there has been a considerable improvement in the understanding of potential 
risk factors for AD, the processes leading to the formation of plaques and tangles in the brain, and 
the brain regions that are affected. Research has shown AD to be a complex disorder, which appears 
to be influenced by genetic components, vascular risk factors, socio-economic conditions and 
environmental and lifestyle aspects. 
 
2.3) Prevalence of AD 
 
Alzheimer's disease International (ADI), an umbrella organisation for national Alzheimer's 
Associations, in their 2009 World Alzheimer Report, estimated that there were 35.6 million people 
living with dementia worldwide in 2010. This is set to increase to 65.7 million by 2030 and 115.4 
million by 2050.  
In the 2013 World Alzheimer report the prevalence of dementia in sub-Saharan Africa was greater 
than that reported in 2009 (4 vs 4.76%). More than two-thirds of dementia cases live in low and 
middle income countries (LMIC) (http://www.alz.co.uk/research/G8-policy-brief). 
Understanding the global burden of AD is important for 2 reasons: 
I. It allows for increased awareness of AD in both developed and lower income countries. 
Increased awareness, in turn, will lead to better identification and management of the 
disease and also more effective support for patients and their families (Patel et al. 2001).    
II. Demographic ageing is proceeding more rapidly in LMIC compared with higher income 
countries (ADI 2009). As a result, chronic non-communicable diseases assume a greater 
significance in LMIC. We do not know how many older persons in South Africa are living 
with dementia and AD, and which sectors of the population are most severely affected 
by the disease.  
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2.4) Clinical presentation and diagnosis of Alzheimer’s disease 
 
2.4.1)  Clinical features 
 
The most prominent cognitive deficit in AD is memory. In AD, episodic memory is predominantly 
affected first and immediate recall or working memory spared. Language and visuo-spatial deficits 
appear as the disease progresses. The latter manifests as an impairment in topographical memory 
i.e. getting lost and confused in previously familiar places. Frontal lobe features and behavioural 
manifestations generally appear late in the disease process. At least 40% of persons have associated 
delusions and hallucinations (Rossor 1993). AD can affect all parts of the brain, but each person is 
affected differently as the disease progresses.  
 
Figure 2.2: Alzheimer’s disease and affected lobes of the brain 
 
 
Anne C. Poinier 
Healthwise incorporated 
https://myhealth.alberta.ca/health/Pages/conditions 
 
 
 
 2.4.2) Neuropathology of Alzheimer’s disease 
 
Neurofibrillary tangles (NFTs) and amyloid or senile plaques are the neuropathological hallmarks of 
AD (Selkoe 1991, Tomlinson et al. 1970; Roth et al. 1996). 
NFTs are intracellular nerve cell abnormalities. They are composed of twisted protein fibres found in 
the cytoplasm of neurones. In AD, these protein fibres are made up of abnormal 
hyperphosphorylated tau protein – a protein that functions in stabilising microtubules and forms an 
integral part of the neuronal cytoskeleton. Aggregation of tau protein leads to a disturbance of the 
19 
 
microtubule network. As a consequence of the latter, axoplasmic flow is disrupted and the neuronal 
cells collapse (Rossor 1993) (Figure 2.3).  
Amyloid plaques are extracellular nerve abnormalities composed of dystrophic axons and dendrites, 
with a central amyloid core. The main component of these plaques is amyloid β (Aβ). Aβ is processed 
from amyloid precursor protein (APP) by the action of β-secretase and ϒ-secretase enzymes. Rare 
genetic mutations in the gene coding for APP result in abnormal cleaving of APP and the production 
of amyloid β fragments, Aβ1-40 and Aβ1-42 (Chartier-Harlin et al. 1991). Aβ1-40 is soluble and is found in 
cerebrospinal fluid (CSF) and brain interstitial fluid (Masters et al. 1985). Both forms of amyloid are 
found in plaques but Aβ1-42 is less soluble and therefore has a greater propensity to aggregate and 
form plaques (Masters et al. 1985).  
 
Despite many hypotheses on the causes of AD in recent times, the amyloid hypothesis remains the 
most widely accepted theory and the most investigated over the past 20 yrs. In short, this theory 
implies that deposition and accumulation of Aβ in the brain is the primary factor driving AD 
pathogenesis (Selkoe 1991). The pathological process involving the formation of neurofibrillary 
tangles containing tau protein is thought to begin with an imbalance between the production and 
clearance of Aβ (Masters et al. 1985). Aβ is thought to be toxic to brain calls by generating 
inflammatory signals. If the accumulation of Aβ peptides is excessive, this can activate migroglia, the 
macrophages of the brain (Rogers et al. 1988). This results in a pro-inflammatory state that may 
eventually cause neuronal death. 
 
 
Figure 2.3: Amyloid plaque toxicity in Alzheimer's disease 
 
 
 
 
BMC Neuroscience (2008), vol. 9 issue. Suppl 2, S8-S8. 
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2.4.3) Diagnosis 
 
Patient History, Examination and Neuropsychological Tests 
The diagnosis of AD may be challenging for clinicians especially in the early stages of disease. A 
detailed history from the patient and their relatives is essential to obtain the overall picture of 
cognitive decline. Neuropsychological tests are often necessary in the earlier stages of the disease. 
The findings of the physical examination may suggest a cause for dementia. For example, dementia 
resulting from cerebrovascular disease may be accompanied by focal neurological signs. 
Frequently used neuropsychological tests include the Mini-Mental State examination (MMSE) and 
the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX). The MMSE was designed 
to detect patients with cognitive impairment amongst a psychiatric population (Folstein et al. 1975). 
It tests global cognitive function, with items assessing orientation, word recall, attention and 
calculation, language abilities and visuo-spatial ability. The CAMDEX is a standardized instrument for 
the diagnosis and grading of dementia (Roth et al. 1986). The Cambridge Cognitive Assessment - 
Revised (CAMCOG-R) questionnaire forms part of the cognitive section of the CAMDEX and has a 
maximum score of 105. All items of the MMSE are also incorporated into the CAMCOG. In most 
studies the CAMCOG cut-off point of 79 or 80 as suggested by Roth et al. seems satisfactory for 
discriminating between normal subjects and demented patients. 
Clinical Diagnostic Criteria 
In clinical practice, the diagnosis of AD has been based on adherence to clinical criteria, such as the 
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's 
Disease Related Disorders Association (NINCDS/ADRDA) and the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) (McKhann et al. 1994). The NINCDS-ADRDA Alzheimer's Criteria 
(appendix A) were proposed in 1984 (McKhann et al. 1994). These criteria require that a clinical 
diagnosis of possible or probable AD be confirmed by neuropsychological testing whereas a 
definitive diagnosis of AD requires histopathologic confirmation (neurofibrillary tangles and amyloid 
plaques). These criteria have shown good reliability and validity (Blacker et al. 1994) (See appendices 
A and B). 
Pathological classification 
There are 2 commonly used systems to classify AD pathologically. 
1)  Heiko and Eva Braak published the Braak Staging of AD-related NFT and neutrophil threads 
(Braak et al. 1991). This staging system has been frequently used in histopathalogical studies 
(Figure 2.4). NFTs develop and spread in a predictable manner across the brain, providing 
the basis for distinguishing six stages of disease progression: the transentorhinal Braak 
stages I–II represent clinically silent cases; the limbic stages III–IV, incipient AD; and the 
neocortical stages V–VI, fully developed AD (Gotz et al. 2011). 
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Figure 2.4: Braak staging of Alzheimer's disease 
 
 
 
Braak et al. 1991 
 Entorhinal stage (I-II) represents clinically silent periods of the disease with NFT involvement confined to trans-entorhinal 
layer. Limbic stages (III/IV) correspond with clinically incipient AD and neocortical stages (V/VI) represent fully developed 
AD, with NFT involvement of all areas of association cortex. Shading indicates the distribution of NFTs with darker colors 
representing increasing densities. Amyg = Amygdala; EC = Entorhinal cortex; CA1 = Cornus ammonis 1 hippocampal 
subfield; Cg = Cingulate cortex; Prec = Precuneus; 4 = Primary motor cortex; 3-1-2 = Primary sensory cortex; 17 = Primary 
visual cortex; 18 = Associative visual cortex. 
 
 
 
2) The Consortium to Establish a Registry for Alzheimer's disease (CERAD), a multi-centre 
longitudinal study, has recognised standardized instruments for the evaluation of persons 
clinically diagnosed with AD. The most common aspect of the CERAD used relates to Aβ 
plaque score. Other parts of the CERAD include clinical neuropsychological, neuroimaging, 
and neuropathological tests. 
 
The common consensus is to combine Braak and CERAD scores to determine whether there is a high, 
intermediate or low likelihood that post-mortem lesions are AD related (NIA-RI Consensus 1997) 
(Table 2.1). 
Table 2.1: Staging in AD 
 
 
The National Institute on Aging and Reagan Institute (NIA-RI) 
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2.5.) Mild Cognitive Impairment (MCI) 
 
MCI is a syndrome defined as cognitive decline greater than expected for an individual’s age and 
education level, but not severe enough to affect activities of daily living (Petersen et al. 1999). It 
represents a prodromal form of incipient dementia conferring a 10-15% annual risk of converting to 
probable AD (Petersen et al. 1999). Identification of subtle brain changes in persons with cognitive 
impairment prior to disease conversion is important in understanding AD progression. Studies 
evaluating the importance of both clinical and imaging biomarkers early in the disease process are 
becoming more common. Genetic markers, cell-cycle biomarkers, oxidative stress parameters and 
pathological markers (serum Aβ) may be of value in detecting early disease (Gustaw-Rothenberg et 
al. 2010) (See Appendix C). 
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a five-year public-private partnership to 
test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological assessment can be combined to measure the 
progression of amnestic MCI and early probable AD (Risacher et al. 2009). 
 
2.6) Risk factors for the development of Alzheimer’s disease 
 
2.6.1) Age 
 
Many prevalence studies relating advanced age to AD have been conducted in the 1980s and 1990s. 
The majority of these studies have demonstrated that the incidence of dementia and AD is higher 
with advancing age within different population groups (Fratiglioni et al. 1991, Bachman et al. 1993, 
Lindsay et al. 2002). Population studies have shown that less than 1% of 60–64 year olds are affected 
compared with 40% in the elderly over 85 years (Rademakers et al. 2003). Other studies confirm that 
even in the oldest old (>85yrs), the risk of AD is increased (Aronsen et al. 1991, Fratiglioni et al. 
1997). 
Some researchers believe that cognitive decline is a normal consequence of the ageing process i.e. if 
all people live long enough they will eventually develop dementia (Levy 1994). Hippocampal brain 
volume has been shown to decrease with advancing age in cognitively healthy and impaired older 
persons (Jack et al. 1997). Another view is that AD and age are related due to the effect(s) of various 
age-related risk factors which either affect cognition directly, or work together to potentiate 
cognitive decline in older persons (Gao et al.1998). 
 
 
 
 
23 
 
2.6.2) Gender 
 
The 2009 World Alzheimer’s report estimated that there are almost twice the number of women 
compared with men living with AD in America (3.4 million vs 1.8 million) (Herbert et al. 2003). This is 
not surprising as a number of studies have showed that AD is more prevalent in females compared 
with males in different population groups (Corso et al. 1992, Bachman et al. 1992, Fratiglioni et al. 
1997, Friedland et al. 1998). Incident studies have generally found no sex differences (Nilsson et al. 
1984, Bachman et al. 1993, Herbert et al. 2001). Studies reviewing sex differences in the pathologic 
indices of AD have also had mixed results, with most indicating no sex differences (Sandberg et al. 
2001). 
Despite years of research, it is still unclear whether AD is more common in females because they live 
longer, or because they are at a greater risk of AD compared with males. In support of the latter, it is 
thought that oestrogen loss associated with menopause may contribute to the development of AD.  
Study findings have highlighted the protective function of oestrogen on cognition (Paganini-Hill et al. 
1994; Kawas et al. 1997). 
 
2.6.3) Level of education 
 
A low level of education has been linked to AD and dementia (Stern et al. 1994, Letenneur et al. 
1999, Qui et al. 2001 Ngandu et al. 2007). Additionally, low levels of education and other markers of 
low socio-economic status (SES) such as low income, have also been associated with cognitive 
impairment (Evans et al. 1997). 
Karp et al. showed that low education and a poor occupational history early on in life, may play a 
role in the development of dementia later on (Karp et al. 2004). In an earlier study, Evans et al. 
looked at 3 measures of SES namely education, occupational prestige and income, to the risk of AD. 
They found that all 3 measures separately predicted an increased risk of AD (Evans et al. 1997).  
Different hypotheses have been suggested to explain such an association. One explanation is that 
education may increase brain reserve as well as mental activity throughout life which postpones the 
clinical manifestations of AD. Education may also be an indicator of intelligence, socio-economic 
status or other factors related to the first decade of life (Ngandu et al. 2007). These early life factors 
could potentially contribute to AD and therefore could modify disease outcome if prevented early 
enough. This is very relevant in South Africa where the majority of our population is poor, of low 
socio-economic status, poorly educated and of low occupational prestige. 
2.6.4) Genetic Factors 
 
Three genes responsible for early onset AD (EOAD) have been identified: the APP gene located on 
chromosome 21 and the two homologous presenilin genes, presenilin 1 (PSEN1) and presenilin 2 
(PSEN2), located on chromosomes 14 and 1 respectively (Van Broekhoven et al. 1992). The ε4 allele 
of the apolipoprotein gene (ApoE) on chromosome 19 is the only known and well-established risk 
factor for late onset AD (LOAD) (Cedazo-Minguez et al. 2001). 
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2.6.5) Apolipoprotein E (ApoE) 
 
ApoE was first described by Shore and Shore (Shore et al. 1973). It is a polypeptide composed of 229 
amino acids whose main function is to modulate plasma lipoprotein and cholesterol levels. Most of 
ApoE is manufactured in the liver but a small amount is produced locally in the central nervous 
system (Elshourbagy et al. 1985). In the brain, cholesterol released from ApoE particles supports 
synaptogenesis and maintains synaptic connections after brain injury. Human ApoE has three 
common isoforms (ε2, ε3 and ε4) which have different effects on lipid and neuronal homeostasis 
(Farrer et al. 1997). 
The ApoE ε4 allele has been associated with elevated plasma cholesterol and low density lipoprotein 
(LDL) levels and increased risk of cardiovascular disease (Davignon et al. 1988). ApoE ε4 allele is also 
a known risk factor for late onset AD (Corder et al. 1993, Strittmatter et al. 1993, Saunder et al. 
1993, Frisoni et al. 1995, Mahley et al. 2006). Different studies generally agree that ApoE ε4 is the 
strongest genetic risk factor for AD whereas ApoE ε2 is protective against AD (Corder et al. 1993, 
Saunders et al. 1993, Roses 1996). It has been demonstrated that, compared to persons with no ε4 
alleles, individuals with one ε4 allele have a three-fold increased risk of AD while the risk is increased 
twelve-fold in those with two ε4 alleles  (www.alzgene.org).  
The ApoE distribution within different populations is variable. The frequency of ApoE ε4 carriers was 
shown to be the highest in the indigenous Khoi-San population group (“Bushmen”) in South Africa 
compared with other world populations (Sandholzer et al. 1995). The frequency of ε4 carriers is also 
greater in persons of African descent compared with other population groups (Gureje et al. 2006, 
Murray et al. 2006, Joska et al. 2010). 
Magnetic resonance imaging and PET scans have shown that cognitively intact carriers of the ε4 
allele have altered brain structure, decreased brain perfusion and differences in white matter 
compared with non-carriers (Bendlin et al. 2010). Recently Pievani et al. showed that hippocampal 
atrophy was greater in ε4 carriers compared with non-carriers (Pievani et al. 2011). Previous studies 
have reported that both hippocampal atrophy and the ApoE ε4 allele were significantly and 
independently associated with AD (Jack et al. 1998).  
                                                                                                  
ApoE and neurobiological mechanisms of injury in Alzheimer’s disease 
 
 
Physiologically, ApoE is responsible for regulating lipid metabolism in cells by directing the transport, 
delivery and the distribution of lipids from one cell to another (Mahley et al. 2000). In the brain, 
ApoE is mainly produced by astrocytes, and transports cholesterol to neurones via ApoE receptors. 
These ApoE receptors are members of the low-density lipoprotein receptor (LDLR) family (Fryer et al. 
2005).  
The ApoE ε4 allele could cause cognitive impairment via Aβ dependent mechanisms and Aβ 
independent mechanisms. 
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Aβ-dependent mechanisms of injury 
In the early 1990s ApoE ε4 was found to co-exist with amyloid plaques (Namba et al. 1991). The 
ApoE ε4 dosage, heterozygous or homozygous state, has been associated with increased neuritic 
plaques in AD patients at autopsy i.e. patients with AD have higher plaque loads if they are ε4 
carriers compared with ε4 non-carriers and even higher brain amyloid if they are homozygous i.e. 
carry two ε4 alleles (Schmetchel et al. 1993, Tiraboschi et al. 2004). Studies have also demonstrated 
that cognitively healthy middle aged and elderly ApoE ε4 carriers have higher brain amyloid levels 
(Morris et al. 2010). 
The mechanism by which ApoE influences the onset and progression of AD is unclear. ApoE may be 
involved in the clearance of Aβ from the brain parenchyma, perhaps by acting as a molecular 
chaperone molecule for transporting Aβ peptides from the brain into the perivascular/cerebrospinal 
fluid spaces (Holtzman et al. 2000). Biologically, Aβ plaque load and accumulation could therefore be 
related to abnormal Aβ clearance mechanisms rather than excessive Aβ production (Masters et al. 
1985). The ApoE isoforms can affect amyloid clearance in different ways. ApoE ε3 has a higher 
binding affinity for Aβ compared with ApoE ε4, leading to a better clearance of Aβ in ApoE ε3 
carriers but an accumulation of Aβ peptides in ApoE ε4 carriers (Strittmatter et al. 1993; Ma et al. 
1994). Structural analyses have provided insight into the mechanisms of the involvement of ApoE in 
atherogenesis and neurological disease. ApoE has two structural domains: the N-terminal domain 
and the C-terminal domain. The N-terminal domain contains the receptor-binding region and the C-
terminal domain contains the lipid-binding region of ApoE. Impaired function of the N-terminal 
domain of ApoE ε3 results in decreased clearance of lipoproteins and cholesterol and resultant 
hyperlipoproteinaemia (Mahley et al. 2000). In ApoE ε4 carriers, the 2 domains interact, and this 
may account for the neurobiological effects observed in persons with AD. Domain interaction in ε4 
carriers stimulates Aβ production and potentiates Aβ-induced lysosomal leakage and apoptosis (Ye 
et al. 2005). 
As discussed earlier on, the ApoE ε4 allele is associated with an increased risk of atherosclerosis 
(Davignon 1988). Cerebral amyloid angiopathy (CAA) is common in older persons and is associated 
with amyloid deposition in leptomeningeal and cortical arteries. CAA is also a pathological feature of 
AD (Selkoe 2001). The ApoE ε4 allele together with other vascular risk factors for cerebrovascular 
disease, work synergistically to exacerbate AD pathology (Kalmijn et al. 1996). More recently it has 
been proposed that amyloid deposits in arteries trigger a secondary cascade of events including the 
release of inflammatory components,  oxidative stress, alteration of the blood-brain barrier (BBB) 
permeability and leaking of toxic proteins into the brain parenchyma (Rostagno et al. 2007,Bell et al. 
2012). 
Aβ independent mechanisms 
Plausible biological explanations that do not include Aβ peptides, called Aβ-independent 
mechanisms, are less well understood. ApoE ε4 has been shown to be less effective in promoting 
neuronal repair and proper brain functioning compared with the ε3 allele (Sorbi et al. 1995). 
Additionally, ApoE ε3 stimulates neurite outgrowth, whereas ApoE ε4 inhibits it and causes 
cytoskeletal instability (Nathan et al. 1994 and 1995). Mitochondrial dysfunction has been reported 
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in AD, which is modulated by the ApoE genotype, with a greater effect in ε4 than in ε3 carriers 
(Gibson et al. 2000). ApoE also causes greater membrane disruption and impaired synaptogenesis 
compared with ApoE ε3 (Mahley et al. 1997). Lastly, the ApoE ε4 allele has been linked to increased 
neuroinflammation associated with amyloid plaque formation in patients with AD (Guo et al. 2004). 
It is possible that, in humans, both Aβ-dependent and independent effects of the ApoE ε4 allele 
mutually interact, thus potentiating the pathological and clinical expression of AD. Animal studies 
have showed that ApoE ε4 macrophages are associated with increased pro-inflammotory cytokines 
(tumor necrosis factor alpha, interleukin 1beta, macrophage inflammatory protein 1-alpha) 
compared with the ε3 allele (Huebbe et al. 2010). 
 
2.6.6)  Vascular risk factors 
 
The conventional assumption is that there are two distinct forms of dementia: vascular dementia 
(VaD) and AD (Roth 1955). VaD has usually been associated with vascular risk factors and AD 
without. Epidemiological evidence however, indicates that vascular risk factors may be involved in 
the aetiology not only of dementia in general, but also specifically of AD (Kivipelto et al. 2001).  
Although the amyloid hypothesis formed the basis for many investigations, the actual evidence 
available to substantiate the claim that amyloid deposition in the brain is the sole cause of AD, is 
limited. Growing evidence from epidemiological, pharmacological, neuroimaging and animal studies 
have suggested that AD is a vascular disorder caused by impaired cerebral perfusion (de la Torre et 
al. 1997). 
Stroke and AD  
Stroke and AD are no longer regarded as separate disease entities. It has been clear for some time 
that stroke and dementia are related (Snowdon et al. 1997, Pohjasvaara et al. 1998, Kalaria 2000). 
Persons who have had a stroke are twice as likely to develop dementia compared with those who 
are stroke-free (Leys et al. 2005).   
The traditional view is that infarcted brain tissue is associated with dementia (Tomlinson et al. 1970). 
It is not clear however, whether stroke is able to initiate a dementing process with progressive 
deterioration. It is possible that vascular risk factors which are common to both stroke and AD, work 
synergistically with the effects of an infarct to further impair cerebral perfusion and hasten cognitive 
decline (Tatemichi et al. 1990, Gottesman et al. 2010). 
 White Matter Hyper-intensities  
Studies relating to the involvement of ‘’silent” brain injury and its association with AD have added to 
the evidence in support of a vascular cause for AD. Neuroimaging has allowed for the identification 
of cerebral infarcts that are silent but share the same risk factors as stroke (DeCarli et al. 2004). 
White matter hyperintensities (WMHs) is a radiological term for non-specific changes in the cerebral 
white matter which may be detected with high frequency magnetic resonance imaging in older 
persons. Leukoaraiosis (Greek: white rarefaction), are white matter changes seen using computed 
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tomography scanning. Despite having no clinically associated symptoms, it is believed that 
underlying vascular risk factors such as hypertension, diabetes, dyslipidaemia, smoking and atrial 
fibrillation are the primary cause of WMHs (Hachinski et al. 1987). Since these lesions are found in 
cognitively healthy older persons as well impaired individuals, WMHs may be a useful marker of 
normal cognitive ageing and of clinically relevant cognitive decline (Steingart et al. 1987, Bronge et 
al. 2002). 
The presence of WMHs would normally influence a clinician to favour a diagnosis of Vascular 
Dementia. However, in recent neuropathological studies of older persons with AD, it is thought that 
neurodegenerative processes such as gliosis, microglial infiltration, inflammation, and amyloid 
angiopathy may all contribute to WMHs. Some researchers believe that WMHs are more strongly 
associated with neurodegenerative diseases such as AD than with vascular disease (Appel et al. 
2009). 
In summary, it is possible that WMHs precede, coincide with, or result from, vascular and 
neurodegenerative processes. The degree of silent brain injury and WHM accrual over time may be 
directly related to the rate of cognitive decline.  
 
Figure 2.5: White matter hyperintensities on MRI scan 
 
Debette et al. 2010 
 
 
Mechanisms of neuronal injury 
The vascular hypothesis of injury arose when the Neuropathology Group of the Medical Research 
Council Cognitive Function and Ageing Study found that 80% of their sample population group, at 
autopsy, demonstrated vascular abnormalities in the brain and that these were worse in those with 
AD (The Medical Research Council Cognitive Function and Ageing Study (CFAS) 2001). 
This theory implies that vascular risk factors induce neurovascular dysfunction, causing endothelial 
leakage by oxidative stress and inflammation. The latter leads to a hypoperfusion state or ischaemia, 
which is represented radiologically by infarcts and WMHs (de la Torre et al. 2004). White matter 
changes and infarcts are associated with cognitive decline (Steingart et al. 1987, Vermeer et al. 
2003). 
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Thus, in patients with AD, the pathology is often mixed and the amyloid hypothesis alone is not a 
sufficient biological explanation for AD pathology. We can assume that the amyloid hypothesis and 
vascular hypothesis overlap in some way, or act synergistically to produce the cognitive impairment 
in AD. The Honolulu Asia Ageing Study, a community based study in old men, suggested that the 
amyloid burden of AD and vascular pathology both independently contributed to the diagnosis of 
AD. Thus, the co-existence of these two mechanisms is likely to result in a worse cognitive state than 
might be expected if they acted separately (Launer et al. 2008).  
Figure 2.6 explains possible biological mechanisms of interaction and overlap between the amyloid 
and vascular hypotheses of injury in AD proposed by several studies (Iadecola 2010, van Norden et 
al. 2011). The associations are as follows: 
a) Amyloid depositions occur in the brain, the pathological hallmark of AD (Selkoe 1991, 
Tomlinson et al. 1970, Roth et al. 1996). These deposits may also be found in cerebral blood 
vessels (cerebral amyloid angiopathy). Vascular risk factors in older adults are associated 
with amyloid angiopathy, which is characterised by amyloid deposition in the walls of 
leptomeningeal and cortical arteries and arterioles. Amyloid angiopathy is a frequent finding 
in persons with AD (Jellinger et al. 2002). 
 
b) Vascular risk factors such as hypertension and diabetes are associated with an increased risk 
of AD via the vascular pathway discussed previously (Sutton-Tyrell et al. 1997, Budge et al. 
2002, Helzner et al. 2009). They have also been associated with medial temporal lobe 
atrophy (de Leeuw et al. 2006, Dhikav et al. 2011), which is strongly associated with AD 
(Seshadri et al. 2004).   
 
c) Hypoxia and ischaemia, resulting from vascular insufficiency, could induce AD changes via 
the vascular pathway or alternatively join the amyloid pathway by increasing the 
transcription of APP and its cleavage. This would result in an accumulation of AB peptides (Li 
et al. 2009). 
 
d) Decreased cerebral blood flow is also associated with silent brain injury which may be 
represented radiologically by WMHs (Hachinski et al. 1987). A small study has shown that 
WMHs are associated with hippocampal atrophy (e) (Korf et al. 2005). 
 
e) A  peptides are toxic to vascular endothelial cells (Rostagno et al. 2007). Aβ is associated 
with increased tau phosphorylation and increased NFT formation, mitochondrial 
dysfunction, oxidative stress, apoptosis and direct damage to vascular endothelial cell 
membranes (Gotz et al. 2011; van Norden et al. 2011). 
 
f) Cytotoxic effects of Aβ peptide on vascular smooth muscle cells results in vasoconstriction 
and hypoperfusion (Thomas et al. 1996). Recently evidence from animal studies has also 
shown that soluble forms of Aβ also induce arteriolar constriction (Dietrich et al. 2010). 
 
g) Plasma Aβ 1-40 concentrations were also found to be independently associated with the 
extent of white matter hyperintensities in subjects with AD, mild cognitive impairment and 
CAA (Gurol et al. 2006). 
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Figure 2.6: Amyloid and vascular hypotheses in Alzheimer’s disease 
Adapted from van Norden et al. 2011 
 
2.6.7) Nutritional Factors 
 
Vitamin B12 and cognition 
Vitamin B12 (cobalamin) is a water-soluble vitamin with a key role in the normal functioning of the 
brain and nervous system.  Vitamin B12 deficiency occurs in approximately 10% of the general 
population (Allan 2009) and 17% of the demented elderly population (Basun et al. 1994). 
In the late 1990s and early 2000s, researchers highlighted the possibility of two types of vitaminB12 
deficiency. On the one hand there is clinical vitamin B12 deficiency which is associated with 
haematological, neurological, and psychiatric manifestations. Neurological manifestations include 
paraesthesiae, peripheral neuropathy and demyelination of the corticospinal tract and dorsal 
columns of the spinal cord (subacute combined degenerative disease). Psychiatric symptoms include 
impaired memory, irritability, depression, dementia and, rarely, psychosis (Robert et al. 2003). On 
the other hand there is subclinical vitamin B12 deficiency which consists of mild biochemical changes 
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that are consistent with vitamin B12 deficient findings without the clinical manifestations as listed 
above (Lindenbaum et al. 1994, Carmel et al. 1999, Carmel at al. 2006). 
Vitamin B12 deficiency is common in older persons (Pennypacker et al. 1992, Lindenbaum et al. 1994, 
Gale et al. 1996, Clarke et al. 2003, Flood et al. 2006) and is believed to be subclinical rather than 
overt (Rosenberg et al. 1992). The cause of this deficiency is largely unknown, but it is hypothesised 
that age related-achlorydia leads to decreased ability to extract vitamin B12 from food protein 
(Carmel 2008, Allen 2009). Therefore, malabsorption or chronic dietary insufficiency may be a 
common cause of subtle vitamin B12 deficiency in the elderly and is largely undiagnosed (Morris et al. 
2012). 
Epidemiological evidence linking low vitamin status with decline in neurocognitive function in the 
elderly has been described in earlier years (Goodwin et al. 1983). Since then, studies examining the 
relationship between vitamin B12 and cognition have provided evidence of a link between low 
vitamin B12 and poorer cognition (Riggs et al. 1996, La Rue et al. 1997, Clarke et al. 1998, Selhub et 
al. 2000). 
The mechanisms by which vitamin B12 deficiency affects cognition are however, unclear. Researchers 
are not sure if the deficiency affects cognition directly, or if it is a consequence of ageing which 
contributes to the neurodegenerative disease process. Biologically, low vitamin B12 and its effect on 
cognition may be mediated by high plasma levels of the compounds homocysteine and 
methylmalonic acid (MMA) (Carmel 1996). More recently researchers have provided evidence that 
vitamin B12 deficiency is also linked to brain atrophy and white matter changes (Vogiatzoglou et al. 
2008, Smith et al. 2009). 
Classical vitamin B12 deficiency is associated with damage to the white matter in the spinal cord and 
in the brain. This has been attributed to damage to myelin as a result of deficient methylation of 
myelin basic protein (Weir et al. 1999). These white matter changes in the brain have been linked to 
low levels of vitamin B12, MMA and holotranscobalamin (holoTC) (de Lau et al. 2009). In a 
longitudinal study, low-normal baseline vitamin B12 status also predicts whole brain atrophy in 
community-dwelling elderly individuals (Vogiatzoglou et al. 2008).  
Folate and cognition 
Folates are essential components of the human diet and are synthesized by micro-organisms and 
plants. The human body needs folate to synthesize deoxyribonucleic acid (DNA), repair DNA, and 
methylate DNA as well as to act as a cofactor in biological reactions (Mattson et al. 2003).  
Opinions relating to folate deficiency and its effects on the nervous system have differed over the 
last 50 years. At present, the benefits and risks of folic acid supplementation in nervous system 
disorders have received both positive and negative reviews. 
Folate is involved in methylation processes which are essential for brain development during the 
early stages of brain growth (Georgieff et al. 1999). It is also important in maintaining proper brain 
functioning later in life (Selhub et al. 2000). Folate deficiency generally occurs as a result of 
inadequate intake, decreased absorption or impaired metabolic utilization. It is associated with 
congenital neural tube defects, megaloblastic anaemia and psychiatric diseases such as 
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schizophrenia and psychosis (Reynolds 1976). In many cases, patients present with neurological 
symptoms in the absence of haematological signs (Reynolds et al. 1979). 
Several studies have provided evidence of an association between red cell folate, cerebrospinal fluid 
(CSF) folate and more recently plasma homocysteine on the one hand, and cognitive decline and AD 
on the other (Reynolds et al. 1976, Clarke et al. 1998, Bottiglieri et al. 2000, Mattson and Shea 2003, 
Ramos et al. 2005). Folate and vitamin B12 deficiency have shown independent associations with 
neurological abnormalities, but are also linked to elevated homocysteine levels (Ravaglia et al. 2005, 
Kim et al. 2008). Interactions between these nutritional factors and high homocysteine levels have 
been a focus of many studies in Europe and North America and form the basis for much of the 
discussion later on in this chapter. 
In elderly populations, the incidence of folate deficiency is higher and is often related to depression 
and cognitive impairment (Sneath et al. 1973, Clarke et al. 1998). Snowdon et al. showed a 
correlation between low folate and cerebral atrophy which was greater in persons with AD 
compared to those without AD (Snowdon et al. 2000). Other studies have demonstrated that folate 
and vitamin B12 deficiency doubled the risk of AD (Wang et al. 2001). 
The mechanisms by which folate deficiency cause cognitive impairment are not clear. Folate 
deficiency could cause cognitive decline via vascular mechanisms mediated by the consequences of 
high homocysteine concentrations in low folate conditions (pg. 43). Alternatively, folate deficiency 
could lead to changes in the numerous methylation processes in the brain. Folate provides the 
methyl group for the conversion of homocysteine to methionine. Methionine is then activated to s-
adenosyl methionine (SAM), a major donor for several methyltransferase reactions. In low folate 
conditions, SAM levels are low and homocysteine levels are elevated. Low folate levels results in 
damage to DNA and impaired DNA repair. The latter could result in genetic mutations or lead to cell 
apoptosis (Kruman et al. 2000). 
Vitamin B12 and folate treatment in cognitive impairment 
Folic acid supplementation in pregnancy and folate fortification of foods has reduced the incidence 
of neural tube defects especially in developing countries such as South Africa (Sayed et al. 2008). 
Controlled trials examining vitamin B12 and folate supplementation to reduce plasma homocysteine 
concentrations and cognitive decline have resulted in mostly negative findings (Sun et al. 2007, Aisen 
et al. 2008, Malouf et al. 2008). I shall discuss this later on. 
Plasma homocysteine and its interactions and interrelationships are the focal points in this study. 
Robert Clarke has added the ‘homocysteine hypothesis’ to vascular and amyloid theories 
surrounding the aetiology of AD. Clarke, along with other researchers, has identified mild to 
moderately elevated plasma homocysteine levels as a potential modifiable risk factor for AD. It is 
difficult to elaborate on the association between homocysteine and AD. Their interaction is 
complicated by the added effects of ApoE ε4 status, vitamin B12 and folate deficiency as well as 
vascular disease. In the discussion that follows, I shall highlight the main findings in the literature 
pertaining to plasma homocysteine and its relationship to cognitive impairment. 
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2.7) Plasma Homocysteine 
 
Background 
In 1932, Butz and Du Vigneaud, biochemists at the University of Illinois, discovered a new amino acid 
resulting from removal of the methyl group of methionine – a compound regularly consumed in our 
diet (Du Vignead et al. 1999). Homocysteine, as it was named, is a non-protein sulphur containing 
amino acid which occurs naturally in the human body.  
The biomedical significance of plasma homocysteine only became known in the 1960s. Kilmer 
McCully et al. discovered an association between elevated plasma homocysteine levels and 
arteriosclerosis (McCully 1969). These elevated plasma homocysteine levels were the result of 
underlying vitamin B12 and folate deficiencies. The role of nutritional deficiencies and elevated 
plasma homocysteine levels in vascular disease challenged conventional theories regarding 
saturated fats and cholesterol dietary risk factors, and resulted in an explosion of research 
pertaining to plasma homocysteine and its determinants in the years following McCullys’discovery. 
Plasma homocysteine has been implicated in other important disease processes such as rheumatoid 
arthritis, hormonal imbalances, renal failure, cancer and neurodegenerative diseases like AD (Kuhn 
et al. 1998, Wollensen et al. 1999, Wu et al. 2002). 
 
2.8) Homocysteine and AD 
 
The interaction between the determinants of plasma homocysteine and homocysteine is complex 
and often confusing. It is not clear whether these factors act independently or if, when combined, 
act synergistically to potentiate cognitive impairment. 
The determinants of plasma homocysteine concentrations 
Plasma homocysteine refers to the sum of protein-bound, free oxidised and reduced species of 
homocysteine in plasma. It is usually 5-15µmol/L in healthy subjects (Ueland et al. 1993). 
Hyperhomocysteinaemia may be classified as moderate (15–30mmol/L), intermediate (31– 
100mmol/L), or severe (>100mmol/L) (Selhub et al. 2000). Moderate to severe cases of 
hyperhomocysteinaemia are rare and often related to genetic mutations (Selhub et al. 
2000).Elevated plasma homocysteine levels (>15mmoll) are linked to multiple clinical conditions 
such as vascular disease, whereas persons with lower homocysteine levels have overall better 
physical and mental health (Refsum et al. 2006). 
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Table 2.2 summarises the factors that are thought to be causes of elevated plasma homocysteine 
concentrations. For the purposes of this study, I have elaborated on 3 relevant determinants of 
hyperhomocysteinaemia, viz. age, vascular disease and the nutritional factors, vitamin B12 and folate. 
 
Table 2.2 
 Causes of elevated plasma homocysteine levels 
 
 
 
 
Genetic 
 
Methylenetetrahydrofolate reductase (MTHFR)deficiency  
MTHFR defect (rare) 
Cystathionine beta synthase deficiency(CBS) deficiency 
(heterozygotes) 
CBS defect (homocystinuria – homozygotes) (rare) 
Functional methionine synthase deficiency (rare) 
 
 
Nutritional Causes Folic acid deficiency 
Vitamin B12 deficiency 
Vitamin B6 deficiency 
 
Systemic factors Renal disease 
Cancer 
Hypothyroidism 
Psoriasis 
Diabetes mellitus 
Acute phase of stroke or myocardial infarction 
 
 
Physiological factors Increased age 
Male sex 
Menopause 
Race 
 
Drugs Anticonvulsants (phenytoin, carbamazepine) 
Oral contraceptives 
Methotrexate 
Nitrous oxide 
Trimethoprim 
Sulfasalazine 
 
 
 Homocysteine Metabolism (Selhub 1999) 
 
Homocysteine metabolism is at the intersection of two metabolic pathways: remethylation and 
transsulfuration. The remethylation pathway allows for the elimination of the body’s free 
homocysteine. In this pathway, homocysteine receives a methyl group form N-5-
methyltetrahydrofolate (N-5 MTHF) or from betain to form methionine. The reaction with N-5MTHF 
occurs in all tissues and is vitamin B12 dependent and requires the enzyme methionine synthase 
(MS), whereas the reaction with betain occurs in the liver, is vitamin B12 independent and is 
dependent on the enzyme betain-homocysteine-methyltransferase. A considerable proportion of 
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methionine is then activated by ATP to form S-adenosylmethionine (SAM). SAM serves primarily as a 
universal methyl donor to a variety of acceptors. S-adenosylhomocysteine (SAH), the by-product of 
these methylation reactions, is subsequently hydrolysed, thus regenerating homocysteine, which 
then becomes available to start a new cycle of methyl-group transfer. 
In the transsulfuration pathway, homocysteine condenses with serine to form cystathionine 
catalysed by cystathionine β-synthase (CBS). Cystathionine is hydrolysed ϒ –cystathionase (CϒS), to 
form cysteine and α-ketobutyrate.  This process is called transsulfuration because it results in the 
creation of sulphate by-products, which are then excreted in the urine. In addition to the synthesis 
of cysteine, the transsulfuration pathway effectively catabolizes excess homocysteine.  
Homocysteine metabolism in the brain is different from systemic homocysteine metabolism. In the 
liver and kidneys, there is an alternate pathway for remethylation of homocysteine to methionine 
via the action of MS and that is through the action of betain-homocysteine-methyltransferase which 
has not been detected in brain cells. CNS cells and neurones do not seem to express the complete 
transsulfuration pathway, therefore the metabolism of homocysteine in the brain is dependent on 
vitamin B12 and folate. If vitamin B12 and folate are deficient homocysteine is elevated and may cause 
damage via several pathways. 
 
 
Figure 2.7: Homocysteine metabolism 
 
Filip Cristiana and Zamosteanu Nina 
http://www.homocysteine2011.com/homocysteine-metabolism#sthash.VE2jZyl0.dpuf 
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Age, plasma homocysteine concentrations and cognition 
 
Plasma homocysteine concentrations increase with advancing age and many studies have shown a 
positive correlation between these two variables (Selhub et al. 1993, Nygard et al. 1998).  There are 
however, age-related diseases which may account for the elevated plasma homocysteine 
concentrations observed in the elderly. These diseases include renal dysfunction and vascular 
disease (Wollensen et al. 1999, Steingart et al. 1987). Researchers have often questioned whether 
these factors together with age cause elevated homocysteine levels and in this way potentiate 
cognitive impairment or whether they act independently.  Brattstrom et al. showed that plasma 
homocysteine concentrations increased with age, but that this relationship, in turn, was largely 
influenced by serum creatinine concentrations (Brattstrom et al. 1994). Other studies confirm that 
renal function, as measured by serum creatinine concentrations, is a major determinant of plasma 
homocysteine levels (Norlund et al. 1998, Bostom et al. 1999, Wollensen et al. 1999). This 
relationship could be the result of poor kidney function arising in patients with a long history of 
vascular disease (Moustapha et al. 1994).  
 
Vascular disease, elevated homocysteine concentrations and cognition 
 
In the 1980s, and with improvements in quantifying plasma homocysteine concentrations (Refsum 
et al. 1985), it became generally accepted that hyperhomocysteinaemia was a potent independent 
risk factor for atherosclerotic vascular disease (Clarke et al. 1991; den Heijer et al. 1996; Selhub et al. 
1995; Ueland et al. 2000).  
Clarke established that elevated homocysteine levels were independently associated with vascular 
disease (Clarke et al. 1991). Boushey et al. concluded that homocysteine was an independent graded 
risk factor for arterioscleotic vascular disease. The odds ratio of cardiovascular disease with a 5µmol 
increment in homocysteine concentration was 1.5, and the odds ratio for cerebrovascular disease 
with the same increment in homocysteine concentration was 1.6 (Boushey et al. 1995). Eikelboom et 
al. demonstrated that moderate elevations in plasma homocysteine concentrations were also 
independently associated with vascular disease (Eikelboom et al. 1999). Other studies have also 
shown a link between mild to moderate levels of homocysteine with cardiovascular disease, 
cerebrovascular disease and stroke (Clarke et al. 2002; de Koning et al. 2003). 
Elevated plasma homocysteine levels have also been linked to stroke and myocardial infarction (MI) 
(Bots et al. 1999). As part of the Rotterdam Study, Bots et al. looked at homocysteine levels in a 
cohort of 144 MI participants and 120 stroke participants. They showed that the risk of MI and 
stroke were directly related to plasma homocysteine concentrations in older persons independent of 
age, sex and other vascular risk factors (Bots et al. 1999). These results were supported by other 
researchers (Verhoef et al. 1996, McIlroy et al. 2002). In a meta-analysis, Wald et al. showed a 
graded independent association between plasma homocysteine concentrations and ischaemic heart 
disease (IHD), deep vein thrombosis (DVT) and stroke (Wald et al. 2002). Nygard showed that plasma 
homocysteine was a strong predictor of mortality in patients with confirmed coronary artery 
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disease. Other studies, such as the homocysteine studies collaboration, found that homocysteine 
levels were, at most, a modest predictor of IHD and stroke in healthy populations (Nygard et al. 
1997, Homocysteine Studies Collaboration 2002). 
Previously I discussed WMHs as possible biomarkers for underlying small vessel disease and silent 
brain injury (Hachinski et al. 1987, DeCarli et al. 1999). WMHs are associated with an increased risk 
of stroke (Vermeer et al. 2003) and elevated homocysteine levels are linked to stroke and 
atherosclerotic outcomes (Perry et al. 1995, Bots et al. 1997 and 1999). Studies examining the 
relationship between white matter lesions and plasma homocysteine are few, but the evidence is 
that hyperhomocysteinaemia may be a risk factor for white matter lesions (Wright et al. 2005, Fuh 
2010). A recent study revealed that high plasma homocysteine levels are associated with the 
presence of silent brain infarcts (Seshadri et al. 2008). 
In summary, there is clear evidence to suggest that vascular injury to the brain, both overt and silent, 
is associated with AD and with elevated plasma homocysteine concentrations. By association, 
therefore, elevated plasma homocysteine could causally relate to AD as well. 
Many of the studies which have determined an association between AD and plasma homocysteine 
concentrations have also included vitamin B12 and folate measurements. Due to their closely linked 
metabolic associations, they are frequently studied together to determine the effects on cognition. 
 
Homocysteine, vitamin B12, folate and cognition 
 
The first study reporting the association between plasma homocysteine and AD was published in 
1990 (Regland et al. 1990). Our current knowledge regarding plasma homocysteine and its 
association with cognitive impairment is based on retrospective, prospective and interventional 
study findings. 
Retrospective studies have shown that plasma homocysteine levels are higher in AD patients 
compared with cognitively healthy controls (Clarke et al. 1998, McCaddon et al. 1998, Mizrahi et al. 
2004, Gallucci et al. 2004). Prospective studies following participants over a period of time have 
generally demonstrated that elevated homocysteine concentrations at baseline predicted cognitive 
decline and dementia at a later stage (Seshadri et al. 2002, Ravaglia et al. 2005, Haan et al. 2007, 
Oulhaj et al. 2010). The majority of randomised controlled trials in patients with AD using folate, 
vitamin B12 or a combination of both, have demonstrated that lowering plasma homocysteine levels 
did not prevent cognitive decline (Sun et al. 2007, Aisen et al. 2008). 
In 1998 Clarke et al. hypothesised that elevated homocysteine levels, by then an accepted vascular 
risk factor, may also be relevant to AD. They demonstrated that elevated homocysteine as well as 
low vitamin B12 and folate levels, were present in patients with AD (Clarke et al. 1998). Several other 
studies since then have supported these findings (McCaddon et al. 1998, Selley 2003, Linnebank et 
al. 2010). Although these researchers were not clear as to which factors determined the elevated 
plasma homocysteine concentrations in the participants with AD, the majority described an inverse 
association between homocysteine and vitamin B12 and folate levels i.e. plasma homocysteine 
concentrations increased with lower concentrations of vitamin B12 and folate. 
Several longitudinal studies, with greater participant numbers, subsequently showed that persons 
with high homocysteine levels had a greater risk of Alzheimers’disease compared to those with 
lower homocysteine levels (Seshadri et al. 2002, Ravaglia et al. 2005). Seshadri et al. demonstrated 
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that elevated homocysteine concentrations in cognitively healthy persons was associated with an 
increased risk of AD after a median of 8 years follow-up. They showed that baseline plasma 
homocysteine concentrations greater than 14mmol/l nearly doubled the risk of AD at a later stage, 
and that each 5 mmol/l increment in homocysteine concentration increased the risk of AD by 40%. 
More importantly, the association between homocysteine with cognitive decline was independent of 
age, sex, education, renal function and other vascular risk factors. Other studies supported these 
findings and showed that elevated homocysteine concentrations and low folate levels were 
independent predictors of dementia and AD. Ravaglia et al. reported a 2-fold increase in the risk of 
dementia associated with hyperhomocysteinaemia (>15mmol/l) in an elderly Italian population 
group (Ravaglia et al. 2005). More recently, researchers showed that elevated homocysteine 
concentrations in midlife was an independent risk factor for dementia in women later on in life, and 
that elevated homocysteine levels predicted conversion of MCI to AD (Annerbo et al. 2006, Oulhaj et 
al. 2010, Zylberstein et al. 2011). 
Whilst most studies have shown an association between plasma homocysteine and cognitive 
impairment, few studies by comparison have demonstrated no association between these two 
variables. Some researchers have found that high plasma homocysteine levels were not related to a 
decline in memory scores over time and that age was a significant confounder in all the analyses 
(Luchsinger et al. 2004). Similarly, Kalmijn et al. showed that elevated homocysteine levels were 
associated with advancing age but not with cognitive decline (Kalmijn et al. 1996).  
In several of the studies mentioned above, authors have linked associations between low vitamin B12 
and folate levels with high homocysteine levels and poorer cognition. Cross-sectional studies over 
the past decade have demonstrated a positive relationship between serum vitamin B12 levels and 
cognition i.e. better vitamin status is associated with better cognition. The inverse relationship 
between vitamin B12 and plasma homocysteine concentrations has been well documented in 
literature from European and North American studies (Stabler et al. 1988, Selhub et al. 1993, Ubbink 
et al. 1993, McCaddon et al. 1998). 
A few studies have demonstrated that plasma homocysteine concentrations correlated negatively 
with MMSE scores, and that serum vitamin B12 and serum folate levels were positively correlated 
with MMSE scores (Bernard et al. 1998, Stewart et al. 2002; Duthie et al. 2002, Hin et al. 2006). 
Seshadri et al. found that homocysteine and vitamin B12 and folate were negatively correlated, and 
that vitamin B12 and folate were positively correlated with cognition (Seshadri et al. 2002).  
Important evidence of these associations was identified by Robert Clarke who reported an 
association between raised plasma homocysteine levels, low serum vitamin B12 and low serum folate 
with confirmed histological changes in participants with AD (Clarke et al. 1998). The vast majority of 
studies subsequently have produced equivocal findings (Quadri et al. 2004, Kim et al. 2008). Most 
have indicated that both vitamin B12 and folate together are associated with cognitive impairment 
but failed to show that low vitamin B12 concentrations in isolation was a risk for AD and dementia 
(Wang et al. 2001). Evidence for an association between folate alone with AD or dementia has been 
more consistent. The majority of these authors agreed that lower folate levels are associated with 
cognitive decline (Ramos et al. 2005, Ravaglia et al. 2005, Kim et al. 2008). 
There are several theories that might explain the difficulty in establishing a clear link between low 
vitamin B12 concentrations and poor cognition. Firstly, it is more useful to identify cognitive 
impairment in persons with low vitamin B12 levels than to look for low vitamin B12 concentrations in 
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cognitively impaired persons (Smith et al 2009). This is because many other factors, in addition to 
low levels of vitamin B12 levels, could account for the cognitive impairment in AD.  
Secondly, total plasma vitamin B12 concentrations are thought to be poor markers of vitamin status 
in tissues (Refsum et al. 2006). The vitamin B12 carrier protein holotranscobalamin (holoTC), plasma 
homocysteine concentrations or methylmalonic acid (MMA) could more accurately represent the 
tissue availability of vitamin B12 compared with total plasma B12 (McCracken et al. 2006). Vitamin B12 
is carried on one of two carrier proteins, haptocorrin and transcobalamin. Transcobalamin, when 
saturated, becomes holoTC. HoloTC binds less than 25% of cobalamin but is considered to be more 
biologically active because it transports cobalamin to various cells in the body whereas haptocorrin 
does not. Therefore, measurements of holoTC provide a more accurate representation of the tissue 
availability of vitamin B12 than the serum B12 (Refsum et al. 2006). 
Thirdly, the association between vitamin B12 status and cognition is influenced by the folate status of 
the population studied. In the 1940s and 1950s high levels of folic acid were used to treat anaemia 
(Reynolds 1976). Despite the improvement haematologically, low doses of folate could aggravate 
neurological symptoms associated with vitamin B12 deficiency and potentiate cognitive impairment 
(Reynolds 1976, Savage et al. 1995). Selhub et al. showed that in a folic acid fortified population 
group, the high folic acid/low vitamin B12 combination (<148pmol/) worsened cognition whereas the 
normal folate/low vitamin B12 combination improved cognition (Selhub et al. 2009). A more recent 
study showed that the combination of high folate levels and low-low normal vitamin B12 
concentrations (187-256pmol/l) predicted cognitive decline (Morris et al. 2012). In another study 
however, authors showed that the high folate/low B12 combination in a non-folate fortified 
population, reduced the risk of cognitive impairment (Doets et al. 2013). Therefore, the safety of 
folic acid fortification especially in older persons, who are at a higher risk of vitamin B12 deficiency, is 
uncertain. 
Finally, some studies have made no distinction between clinical and subclinical vitamin B12 deficiency 
as it is understood today (Carmel 2012). Additionally, there are no clear biological vitamin B12 cut-off 
values that has been standardised amongst studies. Some use traditional low/high values, where 
others use groupings of vitamin B12 (low, subclinical, and normal). Although there are very few 
studies which have tried to overcome the failure of initial studies, a longitudinal study in 2007 by 
Clarke et al tried to account for all the discrepancies listed previously. They found that when 
controlling for possible confounding variables, MMA levels, holoTC concentrations and plasma 
homocysteine, biological markers of low vitamin B12 status, predicted cognitive decline over a 10 
year period (Clarke et al. 2007). 
Plasma homocysteine may be causal in AD or a biomarker of underlying nutritional deficiency i.e. 
high levels of plasma homocysteine levels could be toxic to the brain vasculature and neurones, or, 
these high levels could reflect subclinical vitamin B12 deficiency which we know to be prevalent in 
older persons (Flood et al. 2006, Clarke et al. 2003). The interest in homocysteine is because plasma 
homocysteine levels may be lowered using folate, vitamin B12 or a combination. Plasma 
homocysteine may be a modifiable risk factor (Haan et al. 2007). Controlling homocysteine 
concentrations could also have an impact on disease progression (Seshadri et al. 2002). Clarke and 
Smith in their studies both suggested the need to perform randomised controlled trials to determine 
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the relevance of vitamin B12 supplementation for the prevention of dementia (Clarke et al. 2007, 
Smith 2008). 
Homocysteine lowering therapy 
 
Most trials have shown that vitamin B12 and/or folate supplementation does not slow cognitive 
decline (Sun et al. 2007, Aisen et al. 2008).  Malouf et al., in their review, found that folate and 
vitamin B12 supplementation reduced homocysteine levels, but did not alter the cognition in both 
cognitively healthy and impaired participants (Malouf et al. 2008). More recently another meta-
analysis showed that vitamin B12 supplementation alone did not improve cognition in those with or 
without cognitive impairment (Ford et al. 2012).  
Despite these findings, there has been an abundance of evidence from observational studies which 
consistently demonstrate the interrelationships between plasma homocysteine, folate and cognition 
and, to a lesser extent, vitamin B12 and cognition. Plasma homocysteine could still be a modifiable 
risk factor, but standardised criteria for treatment in preventing its adverse effects on cognitive 
function have not yet been established (Morris  2012). Older persons should therefore be 
encouraged to maintain a good dietary intake of vitamin B12 until such standardised criteria become 
available. Smith et al. recently proposed that people who are cognitively impaired with normal  
biochemical vitamin B12 concentrations in the low-normal range (up to 300p mol/l), should be 
treated with vitamin B12 to improve symptoms. The treatment in elderly persons in the same 
biochemical B12 range, who do not show symptoms, is still unclear (Smith et al. 2012). 
 
2.9) Homocysteine and brain atrophy 
 
Brain atrophy in older persons is common. It occurs in both healthy and demented individuals but is 
much more accelerated in persons with AD. Total cerebral brain volume (TCBV) and hippocampal 
volumes are accepted as measures of neuronal loss and have been associated with impaired 
cognitive function and the risk of AD (Seshadri et al. 2004).  
Deposition of tau protein, formation of neurofibrillary tangles and accumulation of Aβ contributes to 
hippocampal atrophy together with damage caused by several other factors. Vascular risk factors, 
hypertension, diabetes, dyslipidaemia and homocysteine may contribute to hippocampal atrophy 
(de Leeuw et al. 2006, Dhikav et al. 2011). Carriers of the ApoE ε4 genotype have been shown to 
have greater temporal lobe atrophy and poorer memory functions than non-carriers (Dhikav et al. 
2011).  
Several studies have highlighted the association between homocysteine and brain pathology. 
Williams et al. found that homocysteine damaged the hippocampus in normal healthy elderly 
persons (Williams et al. 2002). In the Sydney Stroke Study (131 stroke patients, 81 healthy controls), 
higher homocysteine levels were related to increased number of strokes and greater cognitive 
impairment, in particular, frontal-executive function and attention. In the control group, 
homocysteine was related to increased subcortical atrophy (Sachdev 2004).  Most researchers have 
shown an inverse relationship between plasma homocysteine levels and grey matter volume. A 
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recent study concluded that this relationship was due to age and cardiovascular risk factors rather 
than homocysteine itself (Ford et al. 2012). 
More positive associations have been discovered in studies investigating the effects of B vitamin and 
folate supplementation (with subsequent homocysteine lowering) on brain volume. In the VITACOG 
trial, researchers showed that vitamin B treatment decreased plasma homocysteine levels. There 
was a 31.7% reduction in the final homocysteine concentration compared with placebo. They also 
found that the accelerated rate of brain atrophy in elderly patients with MCI was slowed by the 
administration B vitamins (Smith et al. 2008). More recently the same group reported the outcome 
of vitamin B supplementation on cognition in the same study. They concluded that B vitamins 
appeared to slow cognitive and clinical decline in people with MCI, particularly in those with 
elevated homocysteine (de Jager et al. 2012). 
Despite the association between homocysteine and AD, the mechanisms by which they occur remain 
controversial. How homocysteine may predispose, cause and potentiate AD has been the subject of 
many human and animal studies. Potential mechanisms of association between 
hyperhomocysteinaemia and AD may be explained by factors which are common to both entities, 
and by the effects of homocysteine itself on the nervous system.  
 
2.10) Proposed biological mechanisms of homocysteine-induced cognitive impairment  
 
Vascular Mechanisms 
 
Studies of cellular, animal and human models have suggested several mechanisms by which 
homocysteine may be involved in cerebrovascular neuropathology. These biological mechanisms, in 
the context of high plasma homocysteine, ultimately result in cerebral hypoperfusion. This has been 
well described in the vascular hypothesis of injury in AD (pg. 27 figure 2.6). Plasma homocysteine 
could reduce cerebral blood flow by enhancing atherogenesis (Steingart et al. 1987, Vermeer et al. 
2003). This could occur via mechanisms causing endothelial injury or as a result of increased 
thrombosis within vascular cells. 
Homocysteine could also stimulate collagen synthesis causing vascular smooth muscle proliferation 
potentiating atherosclerosis and vascular damage (Tsai et al. 1994 and 1996).  
 
Thrombosis activation 
Normal haemostasis depends, in some measure, on the balance between pro-aggregatory and pro-
thrombotic platelet thromboxane A2, and vascular prostacyclin, which inhibits platelet aggregation 
and is antithrombotic. Homocysteine is believed to cause an increase in platelet thromboxane 
production with enhanced platelet adhesion, without an increase vascular prostacyclin, thereby 
causing vascular thrombosis ischaemia and cell death (Wang et al. 2006).                                                                                                         
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Structural damage    
Normal functioning of the blood- brain barrier (BBB) is critical for proper neuronal function including 
synaptic transmission, remodelling and neurogenesis (Marlatt et al. 2008). Homocysteine alters the 
integrity of the BBB in both AD patients and transgenic mice, facilitating the release of toxic 
molecules into the central nervous system. These molecules potentiate cell damage and death (Zhou 
et al. 2011). 
Oxidative stress 
 
Reduced clearance of reactive oxygen species (ROS) and oxidative deactivation of nitric oxide (NO), 
produce an imbalance in the oxygen homeostasis in the brain (Weiss et al. 2003, Marlatt et al. 2008). 
The brain has a higher oxygen consumption relative to other parts of the body and it is essential that 
it should be capable of compensating for acute changes in oxygen metabolism and blood flow. If the 
mechanisms controlling the ROS balance in the brain are impaired for any reason, abnormal cellular 
and neural processes could occur. Elevated plasma homocysteine levels could increase the 
production of ROS, increasing calcium influx and enhancing excitotoxicity causing apoptosis 
(Jacobsen 2000). 
Oxidation of homocysteine could also lead to the production of hydrogen peroxide and other ROS 
which may inactivate NO and thrombomodulin (TM). NO is a potent vasodilator and inhibitor of 
platelet aggregation. It is also an important mediator of endothelial, platelet and smooth muscle 
function. At normal plasma concentrations, homocysteine could react with endothelium-derived 
nitrous oxide to form s-nitroso-homocysteine (SNOHcy) which enhances the vasoprotective effects 
of NO. TM expressed on the surface of endothelial cells inhibits coagulation by activation of protein 
C (Figure 2.8). High levels of homocysteine-produced ROS therefore cause impaired vasodilation, 
increased platelet aggregation, enhanced vasoconstriction and impaired TM anticoagulant activity 
(Lentz 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
Lentz 1997. 
Figure 2.8: Oxidative stress: inactivation of nitric oxide 
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Inflammatory response 
Increased plasma homocysteine concentrations result in the increased production of pro-
inflammatory cytokines such as monocyte chemoattractant protein (MCP-1) and Interleukin-8 (IL-8) 
from microglia, the macrophages in the brain. These cytokines cause vascular inflammation which 
promotes atherogenesis (Poddar et al. 2001, Collins et al. 2001).  
Endoplasmic Reticulum Stress (ER stress)  
The endoplasmic reticulum (ER) is the principal site for protein synthesis and maturation in the cell.  
Physiologically, it regulates protein production, folding and modification. ER stress refers to  a state 
where proteins become unfolded or misfolded and tend to accumulate (Lee et al. 2001, Ron et al. 
2001). Oxidative stress, ischaemia and disturbances of calcium homeostasis may induce ER stress 
(Minamino et al. 2010). Overload of misfolded proteins triggers the unfolded protein response (UPR) 
in the ER. The UPR has 2 main funtions:  it aims to restore normal cell functioning by decreasing 
protein translation (Figure 2.9 B) and secondly it aims to provide the necesssary molecular 
chaperones involved in normal protein folding (Figure 2.17 A). If this does not occur within a specific 
time frame, the UPR initiates apoptosis and cell death (Ji and Kaplowitz 2004) (Figure 2.17 D). Plasma 
homocysteine is believed to cause ER stress by disrupting disulﬁde bond formation resulting in 
misfolding of proteins, triggering the UPR and ER-initiated apoptosis (Ji et al. 2004). 
 
Figure 2.9: ER stress and the UPR response 
 
Araki et al. 2003 
 
Mitochondrial dysfunction 
Mitochondria are dynamic ATP-generating organelles that contribute to many cellular functions 
including intracellular calcium regulation, and free radical scavenging. In neurons, mitochondria are 
numerous in synapses and are responsible for energy production. They are major producers of ROS 
and at the same time are targets of ROS toxicity. Elevated homocysteine levels producing ROS 
damage mitochondria causing dysfunctional energy homeostasis and eventual cell death (Pagani et 
al. 2011).  
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Homocysteine hypomethylation 
 
 
It has been shown that elevated homocysteine levels as well as folate and vitamin B12 deficiency 
cause decreased levels of s-adenosyl methionine (SAM), a major methyl group donor, and increased 
concentrations of s-adenosyl homocysteine (SAH), an inhibitor of methyl-transferases (Gharib et al. 
1983). A combination of these changes results in decreased overall cellular methylation (Caudill et al. 
2001).Synthesis and catabolism of several neurotransmitters, as well as the maintenance of DNA 
methylation are all important biological reactions where the methyl groups are required (Mattson et 
al. 2003).  
The lower ratio of SAM/SAH due to elevated homocysteine levels induces DNA damage and 
apoptosis in neuronal cells (Kruman et al. 2000). DNA hypomethylation caused by low vitamin B12 
and folate levels could also be responsible for the activation and overexpression of genes involved in 
AD pathology (Richardson 2003). 
Other markers of vitamin B12 deficiency, such as MMA, could also contribute to the pathogenesis of 
Alzheimers’disease through similar mechanisms such as hypomethylation, Aβ and tau aggregation, 
oxidative stress and apoptosis (Obeid et al. 2006). 
 
 
Aβ elevation and tau phosphorylation   
Studies have demonstrated a positive association between plasma homocysteine levels and AB1-40 
(Irizarry et al. 2005). Recent studies provide evidence that elevated homocysteine levels could 
directly affect Aβ and tau metabolism and cause an increase in amyloid deposition in the brain 
(Obeid et al. 2006; Stanger et al. 2009). Alternatively, homocysteine toxicity could make neurones 
more vulnerable to damage by Aβ peptides (Ho et al. 2001). Homocysteine also increases tau 
phosphorylation through an imbalance between SAM and SAH in experimental animal models (Vafai 
et al. 2002). 
 
Excitatory damage    
  
N-methyl-D-aspartate (NMDA), homocysteate, and N-methyl glutamate were found to be the most 
potent excitatory neurotransmitters causing neuronal necrosis (Olney et al. 1971). Glutamate is an 
important neurotransmitter that plays a key role in long-term potentiation and is important for 
memory and learning. NMDA is an excitotoxin which may bind to the NMDA receptor mimicking the 
action of glutamate. In a study of cultured neuronal and glial cells, homocysteine acted as an agonist 
at the glutamate binding site of the NMDA receptor, causing an increase in cytoplasmic calcium ion 
and ROS influx within cells (McCully 2009). Activation of the NMDA receptor on endothelial cells may 
cause intimal hyperplasia (Chen et al. 1971) and in smooth muscle cells, cellular proliferation 
(Qureshi et al. 2005).  
Gamma (ϒ)-Aminobutyric (GABA) acid is the chief inhibitory neurotransmitter in the central nervous 
system. It plays a role in regulating neuronal excitability throughout the nervous system. 
Homocysteine may compete with GABA at the GABA receptor and may affect its inhibitory function 
(McCully 2009). The overall effect is increased brain excitotoxicity and neuronal damage. 
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Figure 2.10: Summary of the homocysteine neurotoxicity in neurones 
 
Neurotoxic effects of homocysteine (Hcy). Hcy may enter the cell from the extracellular space. It may activate the NMDA 
receptor causing calcium influx and increased ROS within the neuron. ROS causes mitochondrial dysfunction and ER-stress. 
Hcy can also induce neuronal injury through oxidative stress and production of ROS. Elevated Hcy levels are associated with 
increased Aβ deposits, enhanced tau phosphorylation and DNA damage and subsequent neuronal death 
Adapted from:  Stanger et al. 2009 
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Figure 2.11 is a summary of what is currently understood about the associations between plasma 
homocysteine, vitamin B12, folate, ApoE ε4 and cognition.  
 
 Vitamin B12, folate, vascular disease, the ApoE ε4 allele and plasma homocysteine have all 
been associated with cognitive impairment and AD. 
 Improved SES and greater years of education are associated with better cognition. 
 Poor diet, common in older people, could cause deficiencies of folate and vitamin B12 levels. 
Vitamin B12 contributes to cognitive impairment via mechanisms inducing white matter 
changes and atrophy in the brain. Folate is associated with poor cognition through biological 
mechanisms such as homocysteine hypomethylation or via the neurotoxic effects of plasma 
homocysteine.  
 The ApoE ε4 allele is a risk factor for late onset AD whereas the ApoE ε2 allele is protective 
against AD. The ε4 allele is associated with atherosclerosis and vascular disease. It could also 
induce cognitive impairment via vascular pathways or through abnormal Aβ metabolism. 
Genetic risk factors are non-modifiable but there is evidence to suggest that the ApoE ε4 
renders an individual more susceptible to environmental (modifiable) factors.  
 The amyloid and vascular hypotheses have been formulated to explain the pathogenesis if 
AD .This theory implies that vascular factors work synergistically with the effects of impaired 
Aβ metabolism to worsen cognition. 
 Plasma homocysteine (homocysteine hypothesis) has also been causally linked to AD. 
Homocysteine concentrations are inversely related to vitamin B12 and folate levels. 
Homocysteine levels also increase with age. Other age related risk factors such as declining 
renal function and vascular could contribute to cognitive decline include.  
 Plasma homocysteine is causally linked to vascular diseases in the brain, both overt and 
silent. Homocysteine may induce cognitive impairment via mechanisms which cause 
cerebrovascular disease, white matter changes and hippocampal atrophy. Homocysteine has 
been linked to increased amyloid deposition and other neurotoxic mechanisms in the brain. 
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Figure 2.11: Risk factors associated with Alzheimer’s disease 
 
 
 
 
 
 
Summary 
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Plasma homocysteine and its association with cognitive impairment is the main focus of this 
research study. I have discussed the main studies from North America and Europe which have 
demonstrated that elevated plasma homocysteine levels are associated with vascular disease as well 
as neurodegenerative diseases such as AD (Clarke et al. 1991, Seshadri et al. 2002). Plasma 
homocysteine concentrations are also determined by the effects of age and renal function (Nygard 
et al. 1998, Brattstrom et al. 1994).  
Homocysteine concentrations are also largely influenced by vitamin B12 and folate status as a result 
of their closely linked metabolism (Stabler et al. 1988, Selhub et al. 1993). Plasma homocysteine is 
linked to AD via its toxicity to the endothelial blood vessels in the brain. However, other processes 
involving elevated plasma homocysteine levels could also cause damage to neurones. These include 
oxidative stress, inflammation, mitochondrial dysfunction and excitatory damage.  
A large body of evidence suggests that low concentrations of vitamin B12 (which may be better 
represented by high plasma homocysteine levels) are common in older persons. This deficiency is 
associated with impaired cognition. Therefore, it is possible that B vitamin supplementation could be 
used to reduce plasma homocysteine levels which could, in turn, reduce the risk of developing AD. 
RCTs have been largely inconclusive thus far and there are no standardised vitamin B12 and folate 
treatment guidelines available to reduce or slow the rate of cognitive decline.  
The ApoE ε4 allele is a well-known risk factor for late onset AD but its relationship with plasma 
homocysteine has, to my knowledge, not been well researched. Few studies have shown that the ε4 
allele may modify the relationship between plasma homocysteine and cognition (Elias et al. 2008) 
and vitamin B12 and cognition (Vogiatzoglou et al. 2013). 
In South Africa we have no reliable data concerning homocysteine levels and their role in dementia 
and AD. What we do know is that AD is not uncommon in South Africa and the Western Cape, and 
that nutritional deficiency is probably more common in our lower income and older population 
groups. In my research, I hope to test the hypothesis that plasma homocysteine is related to 
cognition. I should also like to test its associations with vitamin B12 and folate in a sample of older 
adults with and without cognitive impairment in the Western Cape. Furthermore, I should also like 
to test the influence of the ApoE ε4 allele on the relationship between plasma homocysteine and 
cognitive function. Research from Europe and North America hints at the promise of homocysteine-
lowering therapy as a way of delaying or preventing cognitive impairment in older persons. My hope 
is that this will also apply to our part of the world where vitamin deficiencies are more common and 
the ApoE ε4 allele more frequent in the rapidly ageing local population.  
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Chapter Three 
 
Aims and Hypotheses 
 
3.1) Introduction 
 
In Chapters One and Two, I discussed how AD relates to certain risk factors, in particular, plasma 
homocysteine and its determinants, vitamin B12 and folate. To our knowledge, little is known about 
homocysteine and its associations with AD in an African and South African context. 
I wanted to study these inter-relationships for the following reasons: 
1. Our impression, and that of colleagues in the fields of cognitive neurology and psychiatry, is 
that cognitive impairment of varying degrees is under-reported and under-diagnosed in 
older persons in South Africa. This project allowed us to determine the association between 
various risk factors and AD in a small group of community dwelling older persons recruited 
from the greater Cape Town metropole. 
 
2. The South African population consists of a large number of people of poor socio-economic 
status. Dietary deficiencies, especially the B group of vitamins, are probably more common 
compared with first world countries.  
 
3. The indigenous population of South Africa is known to have the highest frequency of the ε4 
allele of the ApoE gene in the world (Sandholdzer et al. 1995; Masemola et al. 2007).  
 
4. Homocysteine, vitamin B12 and folate are potentially modifiable risk factors. Early 
identification may prevent or delay the onset of new cases of disease, and slow disease 
progression in those with established AD. 
 
Based on these observations I set out to determine more specifically how plasma homocysteine 
and vitamin deficiencies related to one another and to the degree of cognitive impairment. 
 
3.2) Specific Aims 
 
This study contained both cross sectional and longitudinal components: 
 In a cross sectional analysis, I wished to determine: 
a) The relationship between homocysteine and cognition in all participants.  
b) The relationship between vitamin B12 and folate on the one hand, and cognition on the 
other, in all participants. 
c) The relationship between homocysteine and vitamin B12 and folate in all participants. 
 
For a)-c), I also wished to establish whether these relationships were true for both AD 
and control participants analysed separately. 
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d) To determine the association between homocysteine and cognition in carriers of the 
ApoE ε4 allele compared with non-carriers. 
 
 In the longitudinal analysis I wished to determine whether baseline homocysteine levels 
predict subsequent rates of cognitive decline in patients with established AD over a 1 year 
period. My hypothesis is that participants with high baseline plasma homocysteine levels will 
decline faster when compared to those with lower baseline homocysteine levels. 
 
3.3) Hypotheses 
 
Hypothesis 1 (H1):  Homocysteine levels increase with age. 
My hypothesis is that plasma homocysteine levels increased with age in all participants, AD 
participants and cognitively healthy control participants. As discussed in section 2.7 pg. 35, this 
finding has been a common one in many studies in industrialized countries. 
 
Hypothesis 2 (H2): Plasma homocysteine concentrations are inversely related to vitamin B12 and 
folate. 
I set out to test the hypothesis that baseline plasma homocysteine concentrations would be 
inversely associated with vitamin B12 and folate status in patients with AD, as well as in the 
cognitively healthy participant group. That is, the lower the vitamin B12 and folate concentrations, 
the higher the plasma homocysteine levels.  
Furthermore, I hypothesised that this inverse association between homocysteine and vitamin 
B12/folate would be greater in AD participants compared with cognitively healthy controls. 
 
Hypothesis 3 (H3): Plasma homocysteine concentrations are directly associated with vascular risk 
factors. 
The link between homocysteine concentrations and vascular risk factors have been well documented 
(pg. 35). I set out to test the hypothesis that plasma homocysteine concentrations would be higher 
in persons with vascular risk factors. I also wished to test the hypothesis that persons with increasing 
numbers of vascular risk factors also showed higher homocysteine levels. 
 
Hypothesis 4 (H4): Serum Vitamin B12 and folate are directly related to cognitive function. 
For the most part, studies have shown that lower levels of vitamin B12 are associated with poorer 
cognition (Goodwin et al. 1983, section 2.7 pg. 36). My hypothesis was that when controlling for age, 
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vitamin B12 and cognition would be directly related i.e. the higher the vitamin B12 levels, the better 
the cognitive score; the lower the vitamin B12 levels, the poorer the cognition. 
Similarly, low folate levels have been associated with poor cognition (pg. 36). I wished to determine 
the relationship between cognition and serum folate in all participants, AD participants and 
cognitively healthy controls. 
 
Hypothesis 5 (H5): Plasma homocysteine concentrations are inversely related to cognitive function 
in all participants. 
I wished to test the hypothesis that plasma homocysteine levels are inversely related to cognitive 
function scores in both healthy controls and AD participants i.e. the higher the homocysteine levels 
the poorer the cognitive function. As cognition itself might be related to age, I also wished to 
determine whether age confounded the relationship between plasma homocysteine concentrations 
and cognition. 
 
Hypothesis 6 (H6): The association between plasma homocysteine and cognition is greater in ApoE 
ε4 carriers compared with non-carriers.  
Elias et al showed that homocysteine levels were inversely related to cognitive function, and that the 
association was greater in ApoE ε4 carriers compared with non-carriers (Elias et al. 2007). I therefore 
wished to test the hypothesis that the association between homocysteine and cognition is greater in 
ApoE ε4 carriers compared with non-carriers i.e. the inverse relationship between hcy and cognition 
would have a stronger magnitude of association in participants with 1 or more ε4 alleles compared 
with those with no ε4 alleles. 
 
Hypothesis 7 (H7): AD participants with high baseline serum homocysteine concentrations will 
decline faster when compared to those with lower baseline homocysteine levels. 
I wished to test the hypothesis that participants with AD and a high baseline homocysteine level, had 
a faster rate of cognitive decline over a 1 year period compared to those with lower baseline 
homocysteine levels. Previous studies have demonstrated that individuals with MCI and high-normal 
homocysteine levels declined more rapidly than those with low-normal homocysteine 
concentrations (Oulhaj et al. 2010). 
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Chapter Four 
Methods and Study Design 
 
Introduction 
 
This project formed part of a larger study which aimed to determine, for the first time, whether a 
number of established and putative risk factors for dementia in general and AD more specifically, 
derived from studies in Europe and North America, also applied to our South African population. The 
study sample included elderly volunteers from the greater Cape Town metropole area and elderly 
persons referred from the Memory Clinic at Groote Schuur Hospital.  
The study contained both cross-sectional and longitudinal components. Recruitment of participants 
took place between 2008 and 2012.  
I joined the research team in 2009, and developed an interest in homocysteine concentrations and 
its relevance in AD. Several overseas studies have highlighted the close association between vitamin 
deficiencies and high homocysteine levels. As a result of these, I formulated specific aims and 
hypotheses for study in a sample population from the Western Cape. 
 
4.1) Study Design 
 
This study was a prospective observational study with both cross-sectional and longitudinal 
components. In the cross-sectional analysis, total plasma homocysteine, vitamin B12 and folate were 
studied across the spectrum of cognition, from normal to mild to moderate AD. In the longitudinal 
study, those participants with normal or mild memory impairment had annual repeat cognitive 
assessments after initial testing to determine whether these putative risk factors measured at 
baseline predicted subsequent cognitive decline.   
 
4.2) Sample size 
 
I aimed for a sample size of n=150 for cross-sectional analysis, as previous European and North 
American Studies have shown this number to be sufficient to produce significant differences in 
plasma homocysteine concentrations. Reasons for the “attrition” included participants declining 
cognitively to the point of no longer being able to give informed consent, increased frailty and death. 
In total, 113 participants were involved in the study. Statistical significance was set at the α level of 
0.05. 
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4.3) Recruitment of Participants: patients and controls 
 
Participants were recruited from the greater Cape Town metropole area. About one third of the 
study sample of elderly participants, both patients and controls, were recruited through the 
Rehoboth Age Exchange, a community organisation and Old Age Home in Hanover Park, a working 
class district in the greater Cape Town metropole. Other potential volunteers for the study 
responded to advertisements, placed in various family practices in Cape Town’s southern suburbs. 
More than half of the demented elderly study population, patients with MCI as well as patients with 
mild or moderate AD, were referred from the Memory Clinic of the Department of Geriatric 
Medicine at Groote Schuur Hospital (GSH) and the Institute of Ageing of the University of Cape 
Town. 
 
Inclusion Criteria 
 participants  >55 years of age 
 cognitively intact (normal) participants or participants with mild to moderate Alzheimer’s 
disease diagnosed according to the NINCDS-ADRDA as possible or probable AD (McKhann 
1994). 
 basic literacy i.e. ability to speak, read and write in English, Afrikaans or Xhosa 
 participants must have had a close relative or someone who knew them well who was 
available to provide information about their cognitive abilities as required in the DECO 
questionnaire. 
 
Exclusion Criteria 
 a major psychiatric disorder e.g. depression. Participants were screened for depression using 
the Geriatric Depression Scale (GDS). 
 another major neurological disorder e.g. Parkinson’s or Huntington’s disease 
 a recent major stroke (within the last 6 months) 
 a significant recent head injury (within the last year) associated with loss of consciousness 
 known HIV/AIDS 
 uncontrolled hypertension 
 uncontrolled diabetes mellitus 
 any medical condition that, in the opinion of the investigator, precluded  the patient from 
participating in the study 
 alcoholism & drug abuse 
 heavy smoking (>20 cigarettes per day) 
 oral steroid treatment (precluded only the cortisol study) 
 no access to a freezer at home (for storage of the salivary samples) 
 illiteracy 
 severe dementia i.e. Mini-mental State Examination (MMSE) score  < 12 
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4.4) Ethics 
 
This observational study was approved by the Research Ethics Committee of the Faculty of Health 
Sciences of the University of Cape Town (REC Ref: 346/2008), and has adhered to the principles laid 
down in the Helsinki Declaration of 2008 (World Medical Association 2008) and South African 
Medical Research Council guidelines for research on human subjects (South African Medical 
Research Council 2002). 
 
4.5) Study Procedure 
 
Baseline visit 
Interested participants from the community and referred elderly persons from the Memory Clinic at 
GSH were screened telephonically to assess whether they met the inclusion criteria for the study. In 
the case of the AD patients, a spouse, son, daughter or relative was contacted. If the participant was 
deemed eligible, an initial appointment was arranged. Participants were interviewed and assessed in 
the Department of Neurology in our research clinic facility at Groote Schuur Hospital (GSH). In the 
early stages of the project, initial meetings took place at the Rehoboth Age Exchange Centre in 
Hanover Park. 
Participants were booked for their cognitive evaluation and clinical assessment on the same day. 
Each participant evaluation took approximately 3 hours in total. Elderly persons who became easily 
fatigued and could not complete the entire evaluation in one session were given a break before we 
completed our assessment.  
Pre-interview and Consent 
At an initial interview, the Détérioration de Cognition Observée (DECO) questionnaire, was 
administered to a relative or someone who had at least monthly contact with the participant over a 
period of three years. Participants were screened for depression, using the Geriatric Depression 
Scale (GDS). Participants with a GDS >7 were excluded from the study. We obtained written consent 
from all suitable participants and their relatives. These assessments are discussed in detail later on 
(see section 4.6 pg. 56). 
Lifestyle and Neuropsychological Evaluation 
Demographic and lifestyle questionnaires were administered in English by the patient and/or 
relative, before the battery of neuropsychological tests were performed. The relevant tests are 
explained in more detail later (see section 4.6 pgs. 56 and 57). 
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Baseline Clinical Assessment  
The clinical assessment of participants included a detailed medical history and a general and 
neurological examination. 
A detailed description of the participant’s past history and current complaints was recorded. This 
included relevant medical and family history e.g. hypertension, diabetes and a family history of AD.  
Cognitive symptoms and other relevant medical complaints were noted. We obtained a detailed 
medication/drug history, including vitamin supplementation, from all participants. A general 
examination included measurements of blood pressure, pulse rate, height and weight. 
Cardiovascular, respiratory, abdominal and a thorough neurological examination were all included in 
the clinical evaluation.  
A history of co-morbid vascular risk factors was obtained. The presence of vascular risk factors were 
presented using the Co-morbid score, a scale based on the number of vascular risk factors obtained 
from the medical history of each participant. The Co-morbid Score ranged from 0-4 and included 
previously diagnosed vascular risk factors viz. hypertension, diabetes mellitus and dyslipidaemia as 
well as a history of current or past smoking. If any one of these individual risk factors were present, a 
score of ‘1’ was ascribed and the final co-morbid score was an addition of the number of risk factors 
present. 
  
Special Investigations 
Blood Investigations 
Blood tests as part of a dementia screen and special research bloods were taken on the same visit as 
the clinical evaluation. These included: 
 Full blood count (FBC),  
 Erythrocyte sedimentation rate (ESR) 
 Electrolytes (sodium and potassium) 
 renal function tests (urea and creatinine)  
 calcium 
 liver function tests- albumin, aspartate transaminase (AST), alanine transaminase (ALT), gamma 
glutamyl transferase (GGT) 
 C-reactive protein (CRP) 
 fasting blood glucose  
 cholesterol 
 thyroid function tests 
 syphilis serology 
 serum vitamin B12 
 serum folate  
 
Specific research blood samples included: 
 
 plasma homocysteine 
 whole blood (containing white blood cell DNA) for ApoE genotyping 
 
Blood storage and processing are discussed further in section 4.7 pg. 58. 
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Neuroimaging 
Participants underwent computerised tomography (CT) scanning at GSH if clinically indicated or for 
diagnostic clarification. Participants referred from the specialist clinics already had neuroimaging 
studies to exclude space occupying lesions as a cause for their cognitive impairment.  
 
4.6) Instruments and Measures 
 
Cognitive evaluation included demographic and lifestyle questionnaires and specific 
neuropsychological tests. See Table 4.1 for a list of all the instruments and questionnaires that were 
used in this study. 
 
Table 4.1: Summary of Instruments and Measures 
Instruments and Measures Brief Explanation Score and Interpretation 
Demographic and lifestyle Measures 
Geriatric Depression Scale (GDS) Self-Rating scale of 15 yes/no 
questions related to how participant 
felt over the past week. 
Scores >7 are indicative of depression 
BADLS (Bristol Activities of Daily 
Living) 
Carer-rating scale assessing 20 
activities of daily living over past 2 
weeks. 
Score 0 indicates total independence 
 
Score 60 indicates total dependence 
The Détérioration de Cognition 
Observée (DECO) 
19 item questionnaire by a 
relative/informant 
 
Scores range from 0 to 38, a low score 
indicating poor performance. 
Neuropsychological Measure 
The Cambridge Examination for 
Mental Disorders of the Elderly 
Revised (CAMCOG-R) 
67 items including 19 item MMSE 
questionnaire 
Scored 0-105. 
Scores < 80 are indicative of dementia. 
 
The Mini Mental State Examination 
(MMSE) 
Measures orientation to place and 
time, immediate recall, short term 
verbal memory, language, construct 
ability and calculation. 
Scored out of 30 
>25 normal 
>10 severe dementia 
10-19: mild dementia 
19-24: Moderate dementia 
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The Détérioration de Cognition Observée (DECO) 
In 1992 Ritchie and Fuhrer developed the DECO from retrospective data based on interviews with 
the relatives of dementia patients. The DECO is a questionnaire containing a series of 19 items 
covering cognitive and behavioural changes which are presented to a relative of a patient likely to 
have cognitive impairment (see Appendix D). Questions focus on memory changes for people, places 
and events. It also includes questions about changes in the participant’s activity level and learning of 
new skills. The respondent indicates whether, compared to last year, the behaviour of the 
participant in these situations is more or less the same (2), less (1) or much less (0) than 1 year ago. 
Scores range from 0 to 38, a low score indicating poor performance. The DECO has a demonstrated 
high internal consistency and test-retest reliability (Ritchie et al. 1996), and has been shown to be 
useful in predicting dementia in South African studies (Lenger et al. 1996). 
 
The Geriatric Depression Scale (GDS) 
In the  assessment of  depression in old age, the Geriatric Depression Scale (GDS) (Brink et al. 1982; 
Yesavage et al. 1983) is currently one of the most widely used depression self-reports. Dementia in 
the elderly is often mistaken for depression and the syndrome of ‘pseudodementia’, characterised 
by psychomotor retardation and memory impairment, may be mistaken for dementia. Brink et al. in 
their study selected 100 items with yes/no answers that had been shown to be useful in 
distinguishing elderly depressed subjects from elderly normal subjects. These questions were 
administered in a self-rating form to 47 subjects. The 30 questions which showed the highest 
correlation with the total score were chosen for inclusion in the GDS. The GDS was found to have 
92% sensitivity and an 89% speciﬁcity when evaluated against diagnostic criteria. 
The GDS Long Form is a 30-item self- report questionnaire in which participants are asked to respond 
by answering yes or no in reference to how they felt over the past week. A Short Form GDS 
consisting of 15 questions was developed in 1986 (Sheikh et al. 1986). Questions from the Long Form 
GDS which had the highest correlation with depressive symptoms in validation studies were selected 
for the short version. Scores of 0-4 are considered normal, depending on age, education, and 
complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate 
severe depression. The GDS-Short Form and GDS-Long Form were found to be highly correlated (r = 
.89) and to have similar high sensitivity rates (Lesher et al. 1994).  
The GDS-Short Form was used in this study. This version is more easily used by physically ill and 
mildly to moderately demented patients who have short attention spans and/or feel easily fatigued. 
It takes about 5 to 7 minutes to complete (see Appendix E). 
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The Bristol Activities of Daily Living Scale (BADLS) 
Activities of daily living refers to everyday tasks that people undertake that do not normally require 
any assistance. In the assessment of persons with suspected dementia, it is important to identify 
whether normal activities of daily life have been compromised and if so, how severely they affect 
everyday life. 
The BADLS is an assessment of the functional capacity of participants. It is administered by a relative 
or carer, and was designed specifically for use in patients with dementia (Bucks et al. 1996). It is an 
assessment of 20 daily living activities e.g. eating, drinking, showering, use of the toilet etc. (see 
Appendix F). Researchers have shown that it has good test-retest reliability and that it correlates 
well with the Mini Mental State examination. The BADLS has a minimum possible score of 0 (totally 
independent) and a maximum score of 60 (totally dependent). South African researchers have made 
use of the BADLS in their studies in elderly persons (Tipping et al. 2006). 
 
The Cambridge Cognitive Assessment - Revised (CAMCOG-R)  
The CAMCOG (Roth et al. 1986) is a neuropsychological test that forms part of the Cambridge 
Examination for Mental Disorders of the Elderly -Revised (CAMDEX). The revised version was 
published in 1995 (Huppert et al. 1995).  
The CAMCOG-R consists of 67 items, including the 19 items from the Mini Mental State Examination 
(MMSE) (Folstein et al. 1975). It was used as a test of cognitive functioning in all participants and was 
slightly modified to suit our South African population e.g. we used a picture of Nelson Mandela 
instead of the Queen. 
The test is divided into 8 subscales:  Orientation, Language, Memory and Learning, Attention, Praxis, 
Calculation, Abstract thinking, and Perception.  
 The orientation subscale is comprised of 10 items taken from the MMSE. 
 In the language subscale, comprehension is assessed through nonverbal and verbal 
responses to spoken and written questions, and expression is assessed through tests of 
naming, repetition, fluency and definitions. 
 The memory subscale assesses remote memory (famous events and people), recent memory 
(news items, prime minister, etc.), and learning (the recall and recognition of non-verbal and 
pictorial information learned incidentally as well as intentionally). Attention is assessed by 
serial sevens and counting backwards from 20. 
 Praxis is assessed by copying, drawing, and writing as well as carrying out instructions. 
 In the calculation subscale, the participant is asked to perform an addition and a subtraction 
question involving money. 
 For the abstraction subscale, the participant is asked about similarities between an apple 
and a banana, a shirt and a dress, a chair and a table, and a plant and an animal. 
 In the perception subscale, the participant is asked to identify photographs of famous 
people and familiar objects from unusual angles, in addition to the tactile recognition of 
coins (Huppert et al. 1996). 
 
The CAMCOG takes approximately 30 min to complete and is scored out of 105. Generally scores 
less than 80 are indicative of dementia. 
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The MMSE is a widely used and well validated screening tool for cognitive impairment. It measures 
orientation to place and time, immediate recall, short term verbal memory, language, constructional 
ability and calculation. It is scored out of 30 with scores greater than 25 generally indicating normal 
cognition. A score of 19 -24 indicates mild cognitive impairment; scores between 10-19 are usually 
associated with moderately advanced cases of AD and scores less than 10 indicate severe 
impairment.  
The total CAMCOG, MMSE and Learning Subscale scores were most frequently used in this study for 
diagnosis and for testing hypotheses related to cognitive function. Dementia-free participants were 
defined as NINCDS-ADRDA criteria negative, CAMCOG scores > 80/105, MMSE ≥ 24/30 and a 
Learning Subscale score ≥ 13/17. 
 
4.7) Blood Investigations 
 
Blood sample collection and storage 
Routine Blood Samples 
These were part of the standard dementia screen and were sent to the routine hospital laboratory, 
the National Health Services Laboratory (NHLS). A summary of blood collection tubes, storage and 
special instructions is given in Table 4.2. 
Research Blood Samples 
Blood samples for plasma homocysteine were collected in a 4ml ethylene-diamine-tetra-acetic acid 
(EDTA) tube and stored on ice. These samples were centrifuged at 4000rpm for 10 minutes in a 
bench top laboratory centrifugation machine within an hour of collection. The supernatants were 
aspirated, aliquotted and stored in a laboratory freezer at -80oC.  
Two 4 ml EDTA-containing blood tubes were collected for ApoE genotyping. These samples were 
centrifuged within the hour and the buffy coat layer containing the white blood cells (and DNA) was 
aspirated. The latter was also stored at -80oC until analysed. The total volume of all blood collected 
did not exceed 40mls. 
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Table 4.2: Summary of blood investigations 
 
Blood Tube Blood Investigation Volume Collected Storage 
Tubes with gel to 
assist serum RBC 
separation 
4 tubes in total 
 
Routine chemistry 
Blood tests 
urea 
creatinine and 
electrolytes (Na, K) 
Calcium 
AST 
ALT 
GGT 
TSH 
CRP 
 
total Cholesterol 
vitamin B12 and folate 
 
RPR screen 
3 x 5mls 
1 x 2mls 
room temperature 
 
 
 
 
 
 
 
 
 
 
 
EDTA tube 
2 tube 
FBC diff & WCC 
Serum homocysteine 
4mls 
4mls 
room temperature 
on ice. Supernatants store at -
80
o
C 
Fluoride tube 
1 tube 
glucose 1-2 mls room temperature 
Citrated tube 
1 tube 
ESR 2mls room temperature 
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Analysis of blood tests 
Blood samples forming part of the routine dementia screen were sent to the National Health 
Laboratory Service (NHLS) Groote Schuur Hospital, and the frozen plasma samples for homocysteine 
analysis were sent to a private laboratory (Path Care) for analysis. 
ApoE genotyping was performed by Mrs Felicity Leisegang in the Department of Chemical Pathology, 
University of Cape Town. 
 
4.8) Research Blood Tests: assay methods 
 
Plasma Homocysteine 
The samples were thawed at room temperature prior to analysis. The Path Care private laboratory 
performed these analyses according to the manufacturer’s instructions. 
Homocysteine was measured using an enzymatic cycling assay. The Beckman DXC Chemistry 
Analyser (Beckman Coulter Inc.) and liquid-stable reagents (Catch Homogenous Enzymic 
Homocysteine reagent) were used by the Path Care Laboratories. The Catch Homocysteine 
enzymatic assay has been formulated into a 3-reagent, homogeneous liquid system. Reagents were 
made up of the following active ingredients: 
 lactate dehydrogenase 
 serine 
 reduced nicotinamide co-factor (NADH) 
 cystathionine β-synthase (CBS) 
 cystathionine β-lyase (CBL) 
 
Homocysteine Quantification Method  
The steps used in the enzyme cycling assay are summarised in figure 4.1. 
Plasma samples containing homocysteine, when mixed with reagent, react with serine to form L-
cystathionine in the presence of the enzyme CBS. L-cystathionine is then converted to 
homocysteine, pyruvate, and ammonia (NH3) with a second enzyme, CBL. The result of using these 
anabolic and catabolic enzymes operating simultaneously is a cycle in which (1) cystathionine and 
homocysteine were continuously interconverted, (2) serine is degraded, and (3) pyruvate and 
ammonia are created.  
Pyruvate is measured by the enzymatic conversion using lactate dehydrogenase to produce lactate. 
This enzymatic conversion reaction requires the cofactor NADH, which is converted to NAD+ 
(oxidized nicotinamide co-factor). The concentration of homocysteine is directly proportional to the 
amount of NADH+ converted to NAD+.  The oxidation of NADH to NAD+ is measured by monitoring 
the absorbance at 340 nm.        
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Figure 4.1: Homocysteine Quantification 
Catch Inc. 
                                                                    
 
                                                   CBS 
Serine +  homocysteine                                   L-cystathionine 
 
 
                                                    CBL 
L-cystathionine                                                Homocysteine + Pyruvate + NH3 
 
 
                                                          LD 
Pyruvate + NADH+                                            Lactate + NAD+ 
 
 
 
 
4.9) ApoE Genotyping 
 
Blood samples for ApoE genotyping were collected in 5ml EDTA-containing blood tubes. 109 buffy 
coat samples were prepared and stored at -80oC. Specimens were sent to the Department of 
Chemical Pathology, University of Cape Town, for ApoE genotyping. 
Restriction Isotyping Method 
The 3 isoforms of the ApoE gene differ in the amino acid sequence at 2 sites: amino acid 112 and 158 
(Figure 4.2). 
 
Figure 4.2 ApoE gene isoforms 
 
 
J Cell Mol Med 2001; 5:254–266. Physiological Reviews 2001; 81: 741–766. http://www.cnsforum.com 
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Restriction Enzyme Isoform Genotyping (restriction isotyping) was used for rapid typing of the ApoE 
isoforms, ε2, ε3 and ε4 (Hixson et al. 1990). This method involved the following processes: 
Step 1: polymerase chain reaction (PCR) Amplification 
ApoE gene sequences that incorporate the region coding for amino acid 112 and 158 were amplified 
using PCR amplification. This method uses cycles of heating and cooling to unravel the double helix 
DNA structure and as a result, allows for DNA synthesis in the presence of DNA polymerases. PCR 
amplification facilitates the construction of thousands of copies of a specific genetic sequence for 
analysis. A primer is added at the end of the amplified sequence to increase its length to 237bp, 
allowing for better strand separation. 
Step 2: Restriction Enzyme Digestion 
A restriction enzyme is one that is able to cut DNA at a specific nucleotide sequence known as a 
restriction site. Restriction enzymes are used to distinguish gene alleles by specifically recognising 
single base changes in the DNA. Our samples were digested with Hha1 restriction enzyme (gcgc) to 
generate specific DNA fragments (Figure 4.3). 
 
Figure 4.3: Restriction Enzyme Digestion 
 
                 (31bp)                      (16bp)               91bp 
ggcacggctgtccaaggagctgcaggcggcgcaggcccggctgggcgcggacatggagga 
 
 
cgtgTgcggccgcctggtgcagtaccgcggcgaggtgcaggccatgctcggccagagcac 
 
                       (18bp)                      48bp 
cgaggagctgcgggtgcgcctcgcctcccacctgcgcaagctgcgtaagcggctcctccg 
 
                                  33bp 
cgatgccgatgacctgcagaagCgcctggcagtgtaccaggccggggcgaattctgt 
 
 
Allele ε3 is shown below. Primers are given in purple and cut sites in red. The two bases of interest are in capital letters with 
the diagnostic restriction enzyme cut site shown in the box. 
 
 
Step 3: Gel Electrophoresis 
Gel electrophoresis is used to separate these DNA fragments according to length. The lab used 10% 
acrylamide gel to separate strands. The patterns formed by the fragments are interpreted to identify 
the different isoforms.  The restriction enzyme cut the PCR fragment in several places resulting in 
several bands some of which were common between all isoforms while others were diagnostic.  
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Step 4: Diagnosis (Table 4.3 and Figure 4.4) 
1. Genotype ε2/ε2 has one 81 base pairs (bp) band. 
2. Genotype ε3/ε3 is diagnosed by the absence of the 81 and 72 bp bands.   
3. Genotype ε4/ε4 has 1 72bp band.  
4. Genotype ε2/ε3 is diagnosed by the presence of the 81 bp band (allele2), no 72 bp band 
(excludes ε4) and the presence of the 48 and 33 bp bands. The 48 and 33 bp band come 
from allele ε3 as allele ε2 does not have these bands. In addition a 19 bp band is also 
present. 
5. Genotype ε2/ε4 has both 81 and 72 bp bands. 
6. Genotype ε3/ε4 is diagnosed by the presence of a 72 bp band (allele ε4), no 81 bp band 
(excludes allele ε2) and the presence of the 91bp band.  The 91 bp band comes from allele 
ε3 as allele ε4 does not have these bands. A 19 bp band is also present. 
 
Table 4.3: Diagnostic Interpretation of ApoE genotyping: Chemical Pathology Lab GSH 
 
Isoform type Diagnostic band sizes  present on 10% acrylamide gel Additional  bands 
ε2/ε2 91       81                                 31  18  16 
ε3/ε3 91                         48    33      31  18  16 
ε4/ε4                   72       48    33           19 31  18  16 
ε2/ε3 91       81              48    33            31  18  16 
ε2/ε4 91       81   72       48    33           19 31  18  16 
ε3/ε4 91              72       48    33           19    31  18  16 
 
Hixson et al. 1990 
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Figure 4.4: Hha1 digested PCR products run on a 10% Acrylamide gel 
 
Dept Chem Pathology, UCT 
 
 
4.10) Vitamin B12 and Folate 
 
Serum folate and vitamin B12 concentrations in our samples were determined using the Elecsys 
Folate III assay and Elecsys Vitamin B12 assays respectively. These were routine automated diagnostic 
tests done at the NHLS at GSH and were carried out according to manufacturer’s instructions.  
These assays are binding radioassays which allowed for in vitro quantitative determination of serum 
folate and vitamin B12 concentrations. Both assays use the competitive test principle. 
Intrinsic factor specific for vitamin B12 and natural Folate Binding Protein (FBP) specific for folate are 
used to determine the concentration of vitamin B12 and folate in the sample.  Sample folate 
competes with added folate (labelled with biotin) for binding sites on FBP (labelled with ruthenium 
complex). Vitamin B12 in the sample competes with B12 (labelled with biotin) for binding sites on 
ruthenium-labelled intrinsic factor complex. Voltage applied to the electrode induces a chemi-
luminescent emission measured with a photomultiplier. Results are then determined using an 
instrument-specific calibration curve provided via the reagent barcode. 
 
 
2/2 3/3 4/4 2/3 2/4 3/4 91 bp 
48 bp 
72 bp 
19 bp 
33 bp 81 bp 
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Clinical diagnostic criteria and classification of participants  
Based on neuropsychological, clinical and biochemical analyses, we were able to classify patients 
into two main groups – those with normal cognition and those with impaired cognition. 
Weekly meetings involved group discussions of each case and an overall diagnosis based on 
cognitive scores, clinical impression and collateral information from the participant’s 
relative/informant. The NINCDS-ADRDA (McKhann et al. 1984) criteria were used to classify 
participants into NINCDS-ADRDA negative (controls). Participants classified as possible or probable 
were included in the AD group. Diagnostic criteria proposed by Petersen et al. were used to identify 
patients with MCI) (See Appendix C). 
Follow-up 
All participants received feedback in the form of a summary letter with baseline blood results and 
cognitive scores. Recommendations for follow-up investigations/treatment were included in the 
letter for participants with abnormal blood results. Results were posted to participants, their 
relatives and/or their general practitioner. One year after the initial assessment, participants were 
invited to undergo repeat cognitive evaluations. The physical examination and blood investigations 
were not repeated at this visit. 
 
4.11) Collation of Data 
 
All data from the larger study were captured on an Excel spreadsheet. These included cognitive test 
scores at baseline and follow-up scores 1 year later. I added data that had relevance to my study: 
demographic data for patients and controls, homocysteine, vitamin B12 and folate concentrations 
ApoE data and Co-morbid scores. In total I compiled a data spreadsheet for 113 participants. 
 
4.12) Data Analysis 
 
To analyse data statistically, I transferred all data onto another spreadsheet in Statistica (version 21), 
the software programme used for data analysis.  All data had to be reorganised into groups for both 
continuous and categorical statistical analysis. The level of significance was set at α=0.05. Further 
details regarding statistical analyses are outlined in Chapter 5.  
 
4.13) Study Process summary 
 
Figure 4.5 is a summary of the methods used in this study. Participant numbers and the attrition rate 
are outlined in figure 5.1. 
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Figure: 4.5: Summary of Methods 
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Chapter Five   
 
Results 
 
5.1) Study summary 
 
The final sample comprised 113 study participants in total, of whom 60 were controls and 53 AD 
participants. Demographic characteristics, cognitive test scores, blood test results and ApoE 
genotyping were collected from all participants at baseline (t1). Follow-up cognitive assessments 
were conducted 1 year after the baseline assessment (t2). In both AD and control participants there 
were losses due to either participant death or to participants declining to be involved in further 
evaluations. Further data losses occurred as a result of missing laboratory data or insufficient sample 
volumes for the appropriate assay (see figure 5.1). 
I used the Shapiro Wilk test to assess whether the continuous variables were normally distributed or 
not. Age was the only variable that was normally distributed (p=0.107). Other variables MMSE1 and 
MMSE2 (p<0.001), CAMCOG1 and CAMCOG2 (p<0.001), Learning Subscale1 and Learning Subscale2 
(p<0.001), serum folate (p<0.001), serum vitamin B12 (p<0.001), years of education (p=0.001) and 
plasma homocysteine (p<0.001) were all found to have non-normal distributions.  
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Figure 5.1: Flow diagram of study process 
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5.2) Demographic characteristics 
 
Table 5.1 shows baseline age, sex and education characteristics of all study participants. 
 
Table 5.1: Participant demographic characteristics 
 All 
participants 
n=113 
Control 
Group 
n=60 
AD group 
n=53 
Statistical comparison AD vs. 
Controls 
 
χ2 df p 
Age  74.8 (8.9) 73.2 (8.9) 76.6 (8.6) -2.02 1 0.043** 
Sex (M:F) 30:83 12:48 18:35 2.8 1 0.093 
Level of 
Education 
10.5 (8-15) 14 (10-17) 8 (7-11) 27.8 1 <0.001* 
Age is expressed in years as mean values with the standard deviations in parentheses 
The level of education is expressed as median number of years with the interquartile ranges (IQR) in parentheses. 
*significant at the 0.01 level 
**significant at the 0.05 level 
 
 
Age 
Age in the study group ranged from 59 to 101 years (M=74.8, SD=8.9). The independent samples t-
test showed that the AD participant group were significantly older (M=76.6 vs 73.2, p=0.045) than 
the control participant group.  
 
Sex 
Overall, there were more females than males in the study population (see table 5.1). These 
differences however, were not statistically significant between the AD and control participant groups 
(χ2=2.8, p=0.093). 
 
Level of education 
The number of years of education ranged from 3 to 33 years in all participants (Mdn= 10.5, IQR= 8-
15). AD participants had significantly lower levels of education compared with controls (Mdn=8, 
p<0.001). 
 
In summary, AD participants were older and had fewer years of education compared with controls. 
 
 
 
 
5.3) Cognitive test scores 
 
Table 5.2 shows baseline cognitive test scores in all participants. 
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Table 5.2: Baseline Cognitive Scores in all participants, AD and Control participants 
 Group 
 
Statistical 
comparisons  
AD vs. Controls 
All participants 
n=113 
Control  
n=60 
AD  
n=53 
U p value 
MMSE1 
(30) 
27 (22-29) 29 (28-29) 22 (18-24) 126 <0.001* 
CAMCOG1  
(105) 
84 (68-93) 92 (88-96) 67 (56-76) 34 <0.001* 
Learning 
Subscale1  
(17) 
12 (8-14) 14 (13-15) 7 (4-10.5) 104.5 <0.001* 
 Scores are given as median values with the IQRs in parentheses. 
* significant at the 0.01 level 
 
Baseline cognitive scores included the MMSE1, CAMCOG1 and the Learning Subscale1. As expected, 
scores of the AD group were poorer compared with control participants (see table 5.2). The Mann 
Whitney U test was used to compare the cognitive scores between the 2 groups. AD participants’ 
scores on all 3 measures of cognition were significantly lower than those of the controls (see table 
5.2: MMSE1: U=126, p<0.001; CAMCOG1: U=34, p<0.001: Learning Subscale1: U=104.5, p<0.001). 
 
5.4) Biochemical Tests 
 
Table 5.3 shows blood measurements for plasma homocysteine, serum vitamin B12 and folate taken 
at baseline. 
 
Table 5.3: Baseline biochemical data for all participants, AD and Control participants 
 
 Group 
 
Statistical comparisons  
AD vs. Controls 
All 
participants 
 
Control  
 
AD  
 
U p 
Plasma hcy 
(mmol/l) 
n=108 
10.2  
(7.3- 13) 
n=59 
9.3 
(6.7-11.2) 
n=49 
10.6 
(8.3-14.95) 
 
1017 
 
0.016** 
Serum 
Vitamin B12 
(pmol/l) 
n=109 
350  
(300-475) 
n=58 
414 
(268- 521) 
n=51 
317 
(199-446) 
 
1219 
 
0.053 
Serum Folate 
(nmol/l) 
n=107 
30 
(21-45) 
n=58 
36 
(23-45) 
n=49 
25 
(19-41) 
 
997 
 
0.007* 
All values are given as medians with IQR in parentheses.  
* significant at the 0.01 level 
**significant at the 0.05 level 
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Plasma homocysteine (hcy) 
Hcy concentrations ranged from 5-28 mmol/l (Mdn= 10.2) and were significantly higher in AD 
participants (Mdn=10.6) compared with controls (Mdn=9.3).  The Mann Whitney U test was used to 
evaluate the difference between the groups (U=1016, p=0.016). 
Vitamin B12 
Serum Vitamin B12 levels ranged from 115- 1468 pmol/l. Participants with AD tended to have lower 
vitamin B12 levels (Mdn=317 pmol/l) compared with controls (Mdn=414pmol/l). This difference 
almost reached statistical significance (U=1219, p=0.053). 
Serum Folate 
Folate levels ranged from 12 to >45 nmol/l. AD participants had lower folate levels (Mdn=25nmol/l) 
compared with cognitively healthy controls (Mdn=36nmol/l). Differences in folate levels between AD 
and control participant groups were statistically significant (U=997, p=0.007). 
In summary, AD participants had lower scores on all cognitive tests compared with controls. 
Participants in this group had higher plasma homocysteine levels and lower vitamin B12 and folate 
levels compared with cognitively healthy controls. 
 
5.5) Baseline ApoE data 
 
The ApoE data were expressed as allelic frequencies (table 5.4), and also described in groups based 
on the presence or absence of the ε4 allele in all participants as well as in the AD and control groups. 
Table 5.4 shows the breakdown of the allelic frequencies amongst all participants, AD and control 
groups. This is represented graphically in figure 5.2. Table 5.5 is a 2x2 table depicting AD and control 
participants with respect to their ε4 carrier status (ε4+ = ε4 carrier, ε4- = ε4 non-carrier).Figure 5.3 is 
a graphic representation. 
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Table 5.4: ApoE allelic frequencies in all participants, AD and control groups 
 
 Group 
. 
Statistical comparisons  
AD vs. Controls 
All participants 
n=109  
Control  
n=58 
AD  
n=51  
 χ2 df p 
ε4 non carriers  
ε2/ ε2 1    1   
ε3/ ε2 17   9   7   0.25 1 0.617 
ε3/ ε3 38   26  13    4.3 1 0.037** 
ε4 carriers  
ε2/ ε4 5  3  2     0.2 1 0.655 
ε3/ ε4 41  18  23   0.61 1 0.435 
ε4/ ε4 7  2  5    1.29 1 0.257 
. Values are expressed as numbers with percentages in parentheses. 
** significant at the 0.05 level 
 
 
 
Figure 5.2: Bar graph showing distribution of ApoE allelic frequencies 
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Table 5.5: A 2x2 table comparing ApoE ε4 carrier status in AD and control participant groups 
 ε4 carrier/ε4 non-carrier and AD/control group cross-tabulation 
 Group   
χ
2
=4.3 
p=0.038** 
 
OR=2.2 
p=0.039** 
CI [0.2,5.97] 
AD  
n (%) 
Control  
n (%) 
 
Total n and (%) 
of ε4 carriers in 
all participants 
 
ApoE                                 ε4+ 
ε4 status                                  
                                          ε4- 
 
                                        Total 
30 (27) 
 
21 (19)   
23 (21)  
 
35 (33)  
53 (48) 
 
56 (52) 
 
109 (100) 
**significant at the 0.05 level 
( ) indicate % in within group as a whole 
 
 
 
 
 
 
 
Figure 5.3:  The distribution of participants in ApoE ε4 carrier and ε4 non-carrier groups 
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From the data it was noted that: 
 
 
 In all participants, ε3/ε4 was the most common genotype (36%) followed by ε3/ε3 (34%), 
ε2/ε3 (16%), ε4/ε4 (6%) ε2/ε4 (4%) and lastly ε2/ε2 (1%). 
 In the AD group, the majority of participants carried at least 1 ε4 allele. In this group, 30 
participants were ε4 carriers compared with 23 in the control group (Table 5.5). The ε3/ε4 
genotype was most common in the AD group (43%), and 9% were homozygous ε4/ε4. 
 In the control group the majority of participants were ε4 non-carriers (64%) compared with 
the AD group (36%). The most common genotype was homozygous ε3/ε3 (44%). 
 
Chi-square analysis was used to compare the AD and control groups with respect to their ApoE 
genotype. With the exception of a significant difference between AD and controls in the ε3/ε3 
genotype (χ2 =4.3, p=0.037), no other comparisons were statistically relevant with respect to the 
genotype (see table 5.4). 
 
In a 2x2 contingency table analysis (Table 5.5), the difference in ε4 allelic status between participant 
groups was significant (χ2=4.3(1), p=0.038). The odds of having AD were 2.2x greater in ε4 carriers 
compared with non-carriers (OR=2.2, p=0.039, CI [0.2, 5.97]).  
In summary, more AD participants carried the ε4 allele compared with controls and ε4 carrier status 
was significantly associated with the presence of AD. 
 
5.6) Co-morbid score  
 
Table 5.6: Baseline Co-morbid Scores in all participants, AD and control participants 
 
 
Co-morbid 
score 
Group 
 
Statistical comparisons  
AD vs. Controls 
All participants 
n=109 
Control  
   n=58 
AD  
n=51 
χ2 df P 
0 31 19 12 1.6 1 0.21 
1 50 26 24 0.08 1 0.78 
2 22 9 13 0.73 1 0.394 
3 5 3 2 0.2 1 0.655 
4 1 1 0  
 Co-morbid score breakdown in all participants, AD and Control groups 
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Figure 5.4: Co-morbid Score breakdown in all participants 
 
 
 
 
Table 5.6 shows the distribution of these vascular risk factors within the study population and 
separately amongst control and AD groups. Figure 5.4 shows the distribution graphically. Group 
comparisons were made using Pearson’s chi-square analysis.  The results showed that there were no 
significant differences between AD and control participants in terms of their co-morbid scores. 
AD participants and controls did not differ significantly in terms of the presence of vascular risk 
factors. 
 
5.7) Results by hypothesis 
 
5.7.1) H1: Plasma homocysteine (hcy) increases with age  
 
Hcy and age were analysed as continuous variables. I used Spearman’s Rank Order Correlation to 
determine the relationship between hcy and age in all participants and also separately in the AD and 
control participant groups.  
Hcy and age were strongly correlated in all study participants, AD and control group (rs= 0.418, 
p<0.001). The magnitude of the association was stronger in the AD group (rs =0.457, p=0.001) 
compared with the control participant group (rs=0.315, p<0.015). 
Table 5.7 summarises these findings and figure 5.5 demonstrates the relationship graphically. 
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Table 5.7: Correlation between hcy and age in all study participants, AD and Control groups. 
Plasma homocysteine 
 
 
 
Age 
                                   Number (n)                Spearman's rho(rs)                   p value 
All Participants  
          108 
 
                  0.418 
 
0.001* 
AD group            49 0.457 0.001* 
Control group  59 0.315 0.015** 
*correlation is significant at the 0.01 level 
**correlation is significant at the 0.05 level 
 
 
Figure 5.5: Association between hcy level and age in A) all participants and B) AD and control 
groups. 
 
 
 
Hypothesis one is therefore confirmed i.e. as the participants’ ages increased, so did their hcy 
concentrations. Hcy levels were significantly related to age in all participants taken together, as well 
as in AD and controls participant groups analysed separately. 
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5.7.2) H2: Hcy concentrations are inversely related to vitamin B12 and folate 
 
I analysed the relationship between hcy and vitamin B12 and folate both continuously and 
categorically.  
 
Continuous variable Analysis 
 
Folate 
 
Spearman’s rank order correlation showed a significant inverse relationship between hcy and folate 
in all study participants (rs=-0.33, p=0.001). This relationship held true for the control group (rs=-0.29, 
p=0.027) and tended towards significance in the AD group (rs=-0.28, p=0.059). Table 5.9 summarises 
these results. 
 
Vitamin B12 
 
Spearman’s rank order correlation showed a significant inverse relationship between hcy and 
vitamin B12 in all study participants (rs=-0.47, p<0.001). This relationship held true for both control 
(rs=-0.32, p=0.014) and AD groups (rs=-0.49, p=0.001), with a greater magnitude of association in the 
AD population group. Table 5.8 summarises the correlation results and figure 5.6 is a graphic 
representation of the relationship. 
 
Table 5.8: Correlation between hcy and serum vitamin B12 levels 
 
Plasma homocysteine 
 
 
Vitamin B12 
 n Spearman’s rho p value 
All Participants 109 -0.47 <0.001* 
AD 51 -0.49 0.001* 
Controls 58 -0.32  0.014** 
*significant at the 0.01 level 
**significant at the 0.05 level 
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Figure 5.6: The relationship between vitamin B12 and hcy concentrations in A) all participants and 
B) control and AD groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.9: Correlation between hcy and folate levels  
 
Plasma homocysteine 
 
 
Folate 
 n Spearman’s rho p value 
All Participants 107 -0.33   0.001* 
AD 49 -0.28 0.059 
Controls 58 -0.29     0.027** 
 
*significant at the 0.01 level 
**significant at the 0.05 level 
 
 
 
In summary, these analyses revealed that hcy levels were inversely related to vitamin B12 levels in all 
participants, as well in AD and control participants. H2 is therefore proven: hcy levels are inversely 
related to serum vitamin B12 and serum folate. 
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5.7.3) H3: Hcy concentrations are directly associated with vascular risk factors.  
 
The Krustal-Wallis statistical test was used to establish whether hcy concentrations increased as the 
co-morbid scores of the participants increased. This analysis showed no significant association 
between vascular risk factors and hcy concentration in all participants (χ2 (4) = 2.8, p=0.587), the AD 
group (χ2 (3) =1.7, p=0.621) and the control group (χ2 (4) =2.8, p=0.593). 
In this study, hcy concentrations did not differ significantly according to the number of vascular risk 
factors. 
Addendum to H1-3: Causes of elevated plasma homocysteine in this study. 
H1-H3 evaluated the relationships between hcy and its various determinants: age, vitamin B12, folate 
and vascular risk factors. 
I used a multiple linear regression analysis with hcy as the dependent variable and age, vitamin B12, 
folate and vascular risk factors as independent predictor variables, to determine which of these 
factors independently predicted hcy concentrations in this study population.  
The results showed that age (β=0.481, p<0.001) and vitamin B12 (β=-0.29, p=0.017) independently 
predicted hcy levels. Serum folate and the presence of vascular risk factors did not predict changes 
in hcy concentrations. (see table 5.10). 
 
Table 5.10: Regression analysis: hcy and independent variables age, vitamin B12, folate and 
vascular risk factors. 
 
Dependent 
Variable 
 
Independent 
Variables 
 
        β                   
 
p value 
 
95% CI 
 
plasma  
hcy (mmol/l) 
 
 age 
 vitamin B12 
 folate 
 Vascular 
risk factors 
 
 
0.48 
-0.29 
-0.12 
-0.006 
 
<0.001* 
0.017* 
0.198 
0.468 
 
[0.14,0.4] 
[-0.1,-0.002] 
[-0.05,0.1] 
[-1.143,0.67] 
Dependent variable hcy, and independent variables age, vitamin B12, folate and vascular risk factors. 
*significant at the 0.01 level 
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5.7.4) H4: Serum vitamin B12 and folate are directly related to cognitive function. 
 
Folate 
Spearman’s rho revealed no association between folate and MMSE1 scores (rs=0.15, 
p=0.118).However, the relationship between folate and CAMCOG1 and Learning Subscale1 scores was 
significant i.e. the higher the folate levels, the higher the CAMCOG1 and Learning Subscale1 scores. 
(CAMCOG rs=0.19, p=0.046, Learning Subscale rs=0.26, p=0.008) (See table 5.11 and figure 5.7). 
 
Table 5.11: Correlation between folate and cognitive score 
 
Serum folate in all participants 
                                                                                                 Spearman rho (rs)                   p value 
MMSE1 0.15  0.118 
CAMCOG1 0.19   0.046** 
Learning Score1 0.26 0.008* 
*significant at the 0.01 level 
**significant at the 0.05 level 
 
Vitamin B12 
To define the relationship between serum vitamin B12 and cognition I analysed the data both 
continuously and categorically. Regression analysis was used to control for age as a possible 
confounding variable. 
Continuous variable analysis  
Cognition and serum vitamin B12 were positively correlated in all study participants i.e. as vitamin B12 
levels increased, cognition improved. 
Table 5.12 shows a summary of the results and figure 5.7 is a graphic representation of the 
relationship between cognitive scores and vitamin B12 in all participants. This relationship was 
statistically significant between vitamin B12 and MMSE1 (p=0.032), CAMCOG1 (p=0.039) and the 
Learning Subscale1 scores (p=0.027). When the groups were analysed separately, there was only a 
significant association between vitamin B12 concentrations and MMSE1 in the AD group (rs=0.31, 
p=0.026). 
 
Table 5.12: Correlation between cognitive scores and serum vitamin B12 levels 
Serum vitamin B12 in all participants 
                                                                                                 Spearman rho (rs)                   p value 
MMSE1 0.235 0.014** 
CAMCOG1 0.198 0.039** 
Learning Score1 0.211 0.027** 
**significant at the 0.05 level 
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Figure 5.7: 
The relationships between serum vitamin B12  levelsand cognition as measures by A) MMSE1,  B) CAMCOG1 
and the C) Learning Subscale1 scores. 
The relationships between folate levelsand cognition as measures by D) CAMCOG1 and the  
E) Learning Subscale1 scores. 
 
 
  
 
 
 
 
 
Categorical analysis 
 
Using guidelines for vitamin B12 levels suggested by Carmel, I divided the vitamin B12 data into 
low/subclinical (<258pmol/l) and normal-high (>258pmol/l) groups (Carmel et al. 2006). A 2x2 
contingency table was used to relate high and low vitamin B12 levels to AD and control groups.  
A total of 109 vitamin B12 data samples (51 AD, 58 control participants) were available for analysis. In 
all participants, 27% samples had a value <258pmol/l and 73% of samples a value >258pmol/l. The 
breakdown within each participant group is shown in table 5.13, and figure 5.8 shows the 
distribution of AD and control participants in low and high vitamin B12 groups. There were more AD 
participants in the low vitamin B12 group compared with controls (16 AD vs. 14 controls). There were 
more controls compared with AD participants in the high vitamin B12 group (44 controls vs. 36 AD), 
but these differences were not statistically significant. 
Despite the differences between groups, statistical analyses revealed that low vitamin B12 levels and 
the presence of AD were not associated with each other (χ2 (1,N=110)=0.608, p=0.286). 
Furthermore, the odds of cognitive impairment (AD status) in the low vitamin B12 group was not 
significantly increased compared with the high vitamin B12 group (OR=2.1, p=0.14, CI [0.79, 5.9]). 
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Table 5.13: Serum vitamin B12 high/low and AD/control group cross-tabulation 
 
 Group   
χ2=2.4 
p=0.122 
 
OR=2.1 
p=0.14 
CI [0.79,5.9] 
  
AD  
n 
Control 
 n  
 
Total  
  n (%) 
 
Vitamin B12                   low 
group                      
                                       high 
                                                
                                                 
16  
 
35 
14  
 
44  
30 (27) 
 
79 (73) 
 
109 (100) 
 
 
 
 
Figure 5.8: Clustered bar chart showing the distribution of AD and control participants in high and 
low vitamin B12 groups 
 
 
 
 
In another analysis, I showed that as the ages of participants’ increased, the MMSE (rs= -0.34, 
p<0.001) CAMCOG (rs= -0.35, p<0.001) and Learning Subscale scores decreased (rs= -0.29, p=0.003) 
i.e. cognition was significantly associated with advancing age. Using regression analysis, I wished to 
analyse the relationship between vitamin B12 and cognition when controlling for age as a possible 
confounding variable.   
 
 
Regression analysis 
 
A single model using a multiple regression method was used for all 3 cognitive measures. Table 5.14 
summarises the indices used to describe the association between vitamin B12 and the cognitive 
scores.  
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MMSE1 
Both independent variables, vitamin B12 and age, accounted for 14% of the variance in MMSE1 score 
(r2=0.14, F (2) = 8.8, p<0.001). Both vitamin B12 concentrations and age made significant predictions 
to the MMSE1 score. For every unit increase in serum vitamin B12 concentrations, MMSE1 scores 
improved by 0.23 units (β=0.23, p=0.012).  
 
CAMCOG1 and the Learning Subscale1 
Similarly, both vitamin B12 concentrations and age made significant predictions to the CAMCOG1 and 
Learning Subscale1 scores. For every unit increase in serum vitamin B12 concentrations, CAMCOG1 
scores improved by 0.19 units (β=0.19, p=0.036), and the Learning Subscale1 score by 0.21 units 
(β=0.21, p=0.024).  
These variables accounted for 13% of the variance in CAMCOG1 score (r
2=0.13, F (2) =8.4 p=0.001) 
and 10% of the variance in the Learning Subscale1 score (r
2=0.1, F (2) =5.5, p=0.005). 
 
Age had the opposite effect on all 3 measures of cognition. A unit increase in the age of the 
participants resulted in a 0.28, 0.29 and 0.21 unit decline in the MMSE1 (β=0.28, p=0.003), CAMCOG1 
(β=0.29, p=0.002), and the Learning1 (β=0.21, p=0.024) scores respectively.  
 
 
Table 5.14:  H4 Multiple linear regression 
 
  
Variable 
 
        β                   
 
p value 
 
95% CI 
 MMSE1 
 
 
 vitamin B12 
 age 
 
0.23 
-0.28 
 
 
      0.012** 
    0.003* 
 
[0.001 ,0.012] 
[-0.24,-.0.005] 
 CAMCOG1  
 
 
 vitamin B12 
 age 
    
0.19 
-0.29 
 
 
      0.036** 
    0.002* 
 
 
[0.001, 0.004] 
[-0.88,-0.2 
 Learning1   
 vitamin B12 
 age 
 
 
0.21 
-0.2 
 
     0.024** 
     0.032** 
 
[0.001,0.01] 
[-0.18.008] 
Dependent variables MMSE1, CAMCOG1 and Learning Subscale1, and independent variables vitamin B12 and age.  
 *significant at the 0.01 level 
** significant at the 0.05 level 
 
 
In summary, continuous analyses revealed significant positive relationships between folate and 
CAMCOG and the Learning Subscale scores. The relationship between vitamin B12 and all cognitive 
measures (MMSE, CAMCOG and the Learning Subscale) in all participants was significant but did not 
hold true for AD and control groups when analysed separately. However, in a categorical analysis, 
there was no association between AD cognitive status and vitamin B12 levels.  
Folate however, showed no significant association with MMSE1 score. Regression analysis 
demonstrated that both vitamin B12 and age independently predicted cognitive scores. 
H4 is therefore proven with respect to vitamin B12. Vitamin B12 concentrations were independently 
and significantly associated with cognition: as the vitamin B12 levels increased, cognitive scores 
increased. Folate did not show any relationship with MMSE1 in this study.  
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5.7.5) H5: Hcy concentrations are inversely related to cognitive function in all participants 
 
To determine the relationship between hcy levels and cognitive function as measured by the 
baseline MMSE1, CAMCOG1 and the Learning Subscale1, I analysed the data both as continuous and 
as categorical variables.  
Continuous variable analysis 
Spearman’s rank order correlation was used to determine the relationship between hcy and 
cognition in all study participants. The analysis revealed an inverse association between hcy and 
MMSE1 (rs=-0.276, p=0.004), CAMCOG1 (rs=-0.267, p=0.005) and the Learning Subscale1 (rs=-0.259, 
p=0.007) i.e. as hcy concentrations increased, cognitive function deteriorated. This inverse 
association was not significant when analysed in control and AD groups separately. 
Table 5.15 summarises these findings and figure 5.9 is a graphic representation of the relationship. 
 
Table 5.15: Correlation between hcy and MMSE1, CAMCOG1 and the Learning Subscale1 at baseline 
in all study participants. 
Plasma homocysteine 
                                                                                              Spearman rho(rs)                       p value 
MMSE1  -0.276          0.004* 
CAMCOG1 -0.267 0.005* 
Learning Subscale1  -0.259 0.007* 
*correlation is significant at the 0.01 level 
 
 
Figure 5.9: The relationship between hcy concentration and A) MMSE1, B) CAMCOG1 and C) 
Learning Subscale1 scores in all participants. 
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Categorical analysis 
Using guidelines set out by the Path Care Laboratory in South Africa (Fiekerstrand et al. 1993, Clarke 
et al. 1998), I divided the hcy data into low (<15mmol/l) and high (>15mmol/l) groups. I used a 2x2 
contingency table to compare high and low hcy concentrations in AD and control participants. 
A total of 108 samples were available for analysis, 91 samples with a value <15mmol/l and 17 with a 
hcy concentration >15mmol/l. Figure 5.10 represents the distribution of AD and control participants 
in high and low hcy groups. The graph shows a greater proportion of controls in the low hcy group 
(54 controls vs. 37 AD), and a greater number of AD participants in the high hcy group (12 AD vs. 5 
controls). 
As can be seen by the frequencies cross tabulated in table 5.16, there was a significant relationship 
between high hcy levels and cognitive status (AD vs controls) (χ2 (1, N=108) =5.18, p=0.023). 
Furthermore, the odds of cognitive impairment in the high hcy group was 3.5x greater compared 
with the low hcy group (OR=3.5, p=0.011, CI [1.14, 10.78]). 
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Table 5.16 Hcy high/low and AD/control group cross-tabulation 
 Group   
χ2=5.18 
p=0.023** 
 
OR=3.5 
p=0.011** 
CI 
[1.14,10.78] 
AD  
 
Control  
 
Total 
Hcy group                   high       
N=108 
                                       low         
 
                                      Total 
12 
 
37  
 
 
5  
 
54  
17 
 
91 
 
  108 
 Figures are given in numbers 
**significant at the 0.05 level 
 
 
 
Figure 5.10: The distribution of AD and control participants in high and low hcy groups. 
 
 
 
In summary, the continuous analyses indicated that hcy concentrations were significantly negatively 
correlated with cognitive scores. The categorical analyses indicated that significantly more AD 
participants were in the high hcy group compared with the low hcy group.  
From H1, I noted that hcy concentrations were significantly associated with age. Since AD patients 
were older and had fewer years of education than the controls, these 2 factors could confound the 
association between hcy and cognition. For this reason I decided to perform a regression analysis to 
determine whether the relationship between hcy and cognition was truly independent of other 
potential confounders. 
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Regression Analysis 
Three linear regression models for each cognitive measure were constructed for the analysis. I used 
simple linear regression to make predictions in model 1, and multiple linear regression for 
predictions in models 2 and 3.  
Model 1 
A simple linear regression analysis was used to determine whether cognition as measured by 
MMSE1, CAMCOG1 and the Learning Subscale1, could be predicted by hcy levels. 
In table 5.17, indices of the strength of the variable hcy, in predicting cognitive scores, are 
presented. Results from the regression analysis suggest that 7% of the variance in the MMSE1 
(r2=0.07, F (1) =7.67 p=0.007), 8% in the CAMCOG1 (r
2=0.08, F (1) =9.3, p=0.003) and 7% in the 
Learning Subscale1 (r
2=0.07, F (1) =7.7, p=0.007), could be explained by hcy concentrations. 
 
Hcy significantly predicted changes in MMSE1 score (β=-0.26, p=0.007), CAMCOG1 score (β=-0.28, 
p=0.003), and the Learning Subscale1 (β=-0.26, p=0.007). A 1 unit increase in the hcy concentration 
resulted in a decrease in the MMSE score by 0.26 units. Similarly, for every unit increase in hcy 
concentrations, CAMCOG1 and Learning Subscale1 decreased by 0.28 and 0.26 units respectively (see 
table 5.14).  
 
 
Table 5.17: H4 Model 1 Simple Linear Regression 
 
 MMSE1 CAMCOG1 Learning Subscale1 
r 0.26 0.28 0.26 
r 2 0.07 0.08 0.07 
 
 
 
 
Variable 
 
        β                   
 
p value 
 
95% CI 
 MMSE1  
 hcy 
 
 
-0.26 
 
0.007* 
 
[-0.4,-0.07] 
 CAMCOG1  
  hcy 
 
       
-0.28 
 
0.003* 
  
        [ -1.5,-0.32] 
 Learning1  
  hcy 
 
 
-0.26 
 
0.007* 
 
[-0.35,-0.06] 
Dependent variables MMSE1, CAMCOG1 and Learning Subscale1 scores, and independent variable hcy.  
*significant at the 0.01 level 
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Model 2 
Multiple linear regression was used to determine whether hcy predicted changes in cognition as 
measured by MMSE1, CAMCOG1 and Learning Subscale1 when controlling for age. In table 5.18, 
indices of the strength of 2 independent predictors hcy and age, are presented. 
Results of the analysis revealed that 13% of the variance in MMSE1 score (r
2=0.13, F (2) =7.7, 
p=0.001), 14% of the CAMCOG1 score (r
2=0.14, F (2) =8.2, p=0.001) and 10% of the Learning 
Subscale1 (r
2=0.1, F (2) =5.8, p=0.004), could be explained by hcy and age. 
Additional findings included the following for each measure of cognition: 
MMSE1: When controlling for age, hcy concentrations were not significant in predicting changes in 
MMSE1 score (β=-0.16, p=0.143). Age was the only significant variable within the model: a 1 unit 
increase in the age of a participant resulted in a 0.27 unit decline in the MMSE1 score (β=-0.27, 
p=0.009). 
CAMCOG1: age made significant predictions to the CAMCOG1 score. A 1 unit increase in the age of 
the participant resulted in a 0.26 unit decline in the CAMCOG1 score (β=-0.26, p=0.01). Hcy 
concentrations did not quite reach significance:  a 1 unit increase in hcy concentration resulted in a 
0, 17 unit decline in CAMCOG1 score (β=-0.17, p=0.088).  
Learning Subscale1: hcy concentrations and age as predictor variables tended towards, but did not 
quite reach significance within this model:  a 1 unit increase in hcy concentrations resulted in a 
Learning score decline by 0.18 units (β=-0.18, p=0.077). A 1 unit increase in the age of participants 
resulted in a 0.19 unit decline in the Learning Subscale1 (β=-0.19, p=0.065). 
In summary, hcy was not independently associated with changes in the MMSE1 score. Hcy 
concentrations tended towards significance in explaining the changes in the CAMCOG1 scores. 
Plasma hcy concentrations as well as age tended towards significance in explaining changes in the 
Learning Subscale1 score. 
 
Table 5.18:  H4 Model 2 Multiple linear regression 
 MMSE1 CAMGOG1 Learning Score1 
r 0.36 0.37 0.32 
r 2 0.13 0.14 0.1 
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Variable 
 
        β                   
 
p value 
 
95% CI 
 MMSE1 
 
 
 hcy 
 age 
 
-0.15 
-0.27 
 
 
0.143 
    0.009* 
 
[-0.32 -0.46] 
[-0.25, -0.36] 
 CAMCOG1  
 
 
  hcy 
 age 
    
-0.17 
-0.26 
 
 
    0.088 
    0.01* 
 
 
[-1.2, -0.85] 
[-0.86,-0.12] 
 Learning1   
  hcy 
 age 
 
 
-0.18 
-0.19 
 
0.077 
0.065 
 
[-0.31,-0.16] 
[-0.18, 0.006] 
Dependent variables MMSE1, CAMCOG1 and Learning Subscale1, and independent variables hcy and age.  
** significant at the 0.01 level 
 
Model 3 
 
Prior to analysing model 3 which included a third predictor variable, years of education, I used 
Spearman’s rank order correlation to determine the relationship between 1) age and education, and 
2) education and cognition. 
 
Results showed that the age and education were negatively correlated and that the association was 
significant (rs=-0.276, p=0.003) i.e. fewer years of education were associated with more advanced 
age. Education was positively correlated with all 3 measures of cognition (see table 5.19) i.e. more 
years of education were associated with better cognition. 
 
Table 5.19: Correlation results between years of education and MMSE1, CAMCOG1 and the 
Learning Subscale1 at baseline. 
Years of Education 
                                                                                              Spearman rho(rs)                       p value 
MMSE1  0.59         <0.001* 
CAMCOG1  0.65 <0.001* 
Learning Subscale1  0.47 <0.001* 
*significant at the 0.01 level 
 
 
Table 5.20 summarises the indices used to describe the strengths of the 3 predictor variables in 
explaining the MMSE1 score. The results show that 20% of the variance in MMSE1 could be explained 
by hcy, age and years of education (r2=0.2, F (3) =12.6, p<0.001). Similarly 40% of the variance in the 
CAMCOG1 score (r
2=0.4, F (3) =22.5, p<0.001) and 22% of the variance in the Learning Subscale1 
(r2=0.22, F (3) =9.5, p<0.001) could be explained by these 3 variables. 
 
Hcy concentrations and age were not significantly associated with changes in MMSE1. The number of 
years of formal education was the only significant predictor variable within this model. A unit 
increase in the years of education caused a 0.49 unit increase in the MMSE1 score (β=0.49, p<0.001). 
Similarly for cognitive measures CAMCOG1 and the Learning Subscale1, hcy concentrations and age 
were not significant. A unit increase in the number of years of education resulted in a 0.54 unit 
increase in the CAMCOG1 score (β-0.54, p<0.001) and a 0.36 unit increase in the Learning Subscale1 
score (β=0.36, p<0.001). 
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Table 5.20: H4 Model 3 Multiple linear regression 
 
  
Variable 
 
        β                   
 
p value 
 
95% CI 
 MMSE1 
 
 
 hcy 
 age 
 education 
 
-0.11 
-0.14 
0.49 
 
 
0.23 
0.124 
<0.001** 
 
[-0.26,  0.6] 
[-0.17, 0.2] 
[0.32, 0.67] 
 CAMCOG1  
 
 hcy 
 age 
 education 
    
-0.13 
-0.12 
0.54 
 
 
0.122 
0.182 
<0.001** 
 
[-0.98, 0.12] 
[-0.56, 0.11] 
[1.35, 2.5] 
 Learning1   
 hcy 
 age 
 education 
 
 
-0.15 
-0.1 
0.36 
 
0.127 
0.323 
<0.001** 
 
[-0.27, 0.03] 
[-0.14, 0.005] 
[0.16, 0.5] 
Dependent variables MMSE1, CAMCOG1, Learning Subscale1 and independent variables hcy, age and years of 
education.  
*significant at the 0.01 level 
 
Although continuous variable and categorical analyses suggested that hcy and cognition were 
inversely related to each other, this association did not hold true when controlling for the 
confounding effects of age and years of education. 
 
H5 is therefore not proven, hcy concentrations were not associated with cognition when controlling 
for age or the years of education. 
 
 
5.7.6) H6: The association between hcy and cognition is greater in ApoE ε4 carriers 
compared with non-carriers.  
 
I analysed the data for this hypothesis using correlation and regression analysis.  
 
Continuous variable analysis 
These results showed an inverse relationship between hcy and cognition, with a greater strength of 
association in ε4 carriers compared with ε4 non-carriers (see figure 5.11). The relationship between 
hcy and cognition as measured by MMSE1 (rs=-0.41, p=0.003), CAMCOG1 (rs=-0.39, p=0.003) and the 
Learning Subscale1 (rs=-0.33, p=0.019), was significant in ε4 carriers but not in ε4 non-carriers (see 
table 5.21). 
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Table 5.21: Correlation between hcy concentrations and cognition as measured by MMSE1, 
CAMCOG1 and the Learning Subscale1 in ε4 carriers vs. ε4 non-carriers 
 
 
 
Figure 5.11: The relationship between hcy concentrations and A) MMSE1 B) CAMCOG1 and C) 
Learning Subscale1 scores in ApoE ε4 carriers and non-carriers 
 
 
        Plasma Homocysteine 
 
 
ApoE ε4 
carrier 
status 
  
Cognitive Test 
 
Spearman's rho (rs) 
 
p value 
ε4 + 
 
MMSE1 
CAMCOG1 
Learning Score1 
 - 0.41    
  -0.39    
 - 0.33    
0.003* 
0.003* 
0.019** 
 
 
ε4 - 
 
 
MMSE1 
CAMCOG1 
Learning Score1 
 
-0.08 
- 0.09 
-0.13 
 
0.574 
0.499 
0.331 
*significant at the 0.01 level 
**significant at the 0.05 level 
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We know that hcy levels increase with age and that cognitive scores fall with age. So, could this 
interesting result be explained by the confounding effect of age? 
 
To answer this question, I compared the mean ages of ApoE ε4 carrier and ε4 non-carrier groups. 
Table 5.22 shows the results of the independent samples t-test used in this analysis. 
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Table 5.22: Comparison of the mean ages between ApoE ε4 carrier and ε4 non-carrier groups. 
 
 ε4+ ε4- Statistical analysis 
between ε4+ and ε4- 
Age  
mean (SD) 
 
73.4 (7.9) 
 
76 (9.7) 
t= -1.55 (107) 
p=0.124 
 
There was no statistical age difference between the groups. The association between plasma 
homocysteine and cognition in ApoE ε4 carriers was not confounded by the effect of age. Thus, the 
association between hcy and cognition is greater in ApoE ε4 carriers compared with ε4 non-carriers. 
In fact, this association was only present in ε4 carriers. 
Regression analysis 
In another analysis, I wished to determine whether plasma hcy levels could independently predict 
changes in cognitive scores when controlling for age and ApoE ε4 carrier status. 
I used stepwise regression in a single model consisting of 3 predictor variables, hcy, ε4 carrier status 
and age, and cognition as measured by MMSE1, CAMCOG1 and the Learning Subscale1 as the 
dependent variable.  
 
Table 5.23 is a summary of the results. The variance for age and ApoE ε4 status are shown in Table 
5.23a. The results showed the following: 
 
 
MMSE1 
Hcy concentrations, ε4 carrier status and age accounted for 19% of the variance in MMSE1 scores 
(r2=0.19, F (3) =7.8, p=<0.001). 
Furthermore results showed age and ApoE ε4 carriers made significant predictions to the MMSE1 
score. A 1 unit increase in age and the presence of the ε4 allele resulted in a decline in the overall 
MMSE1 score by 0.35 (β=-0.35, p=0.001) and 0.26 (β=-0.26, p=0.005) units respectively. Hcy 
concentrations were not significant within this model. 
 
CAMCOG1 and the Learning Subscale1 Scores 
Similarly, age, ApoE ε4 carrier status and hcy concentrations accounted for 18% of the variance in 
CAMCOG1 scores (r
2=0.18, F (3) =7.4, p=<0.001) and 16 % of the variance in the Learning score1 
(r2=0.16, F (3) =6.7, p=<0.001). 
 A 1 unit increase in age and the presence of the ε4 allele resulted in a 0.35 (β=-0.35, p=0.001) and 
0.23 (β=-0.23, p=0.013) unit decline in CAMCOG1 scores respectively. Furthermore, results showed 
that if a participant carried the ε4 allele and had a 1 unit increase in age, the overall Learning score 
decreased by 0.28 (β=-0.28, p=0.003) and 0.26 (β=-0.23, p=0.013) units respectively. Hcy 
concentrations made no significant predictions to the CAMCOG1 and Learning Scores. 
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Table 5.23: Stepwise linear regression model: hcy, age and ε4 carriers and cognition as measured 
by MMSE1, CAMCOG1 and the Learning Subscale1 scores 
 
 
Dependent 
Variable 
 
Predictor variable 
 
β 
 
p value 
 
95% CI 
 
 MMSE1 
 
 
 
 
 
 hcy 
 ε4 + 
 age 
 
 
 
-0.07 
-0.26 
-0.35 
 
 
0.501 
0.005** 
0.001* 
 
 
[-0.24,0.12] 
[-4.0,-0.73] 
[-0.29,-0.08] 
 
 CAMCOG1 
 
 
 
 
 hcy 
 ε4 + 
 age 
 
 
-0.08 
-0.23 
-0.35 
 
0.444 
0.013** 
0.001* 
 
[-0.88,0.39] 
[-13.1,-1.56] 
[-0.9,-0.27] 
 
 
 
Learning Subscale1 
 
 
 
 
 
 hcy 
 ε4 + 
 age 
 
 
 
 
-0.13 
-0.28 
-0.26 
 
 
0.191 
0.003** 
0.013** 
 
 
[-0.27,0.06] 
[-3.7,-0.76] 
[-0.21,-0.25] 
*significant at the 0.01 level 
**significant at the 0.05 level 
 
Table 5.23a: Variance in the MMSE, CAMCOG and Learning Subscale scores 
 
Table 5.23a MMSE1 CAMCOG1 Learning Subscale1 
R 0.43 0.42 0.41 
r 2 0.19 0.18 0.16 
 
 
 
In this model, age and ApoE ε4 status were independently associated with cognitive decline. 
In summary, the inverse relationship between hcy and cognition was present in ε4 carriers but not in 
ε4 non-carriers. In a regression analysis, hcy did not predict changes in cognitive scores. 
 
5.7.7) H7: Participants with high baseline hcy concentrations will decline faster when 
compared to those with lower baseline hcy levels. 
 
Neuropsychological evaluations were performed on 92 participants 1 year after the baseline 
examinations. 
The data for this hypothesis were analysed 2 ways. First I used the paired Wilcox Signed Rank test to 
test the difference in median MMSE, CAMCOG and the Learning Subscale scores from the initial 
baseline tests (t1) to the follow-up scores (t2). Second, a simple linear regression was used to 
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evaluate whether high baseline hcy concentrations could predict changes in cognition within the AD 
sample group only.  
Tables 5.24-5.26 show the difference in median scores from t1-t2 in all 3 cognitive domains. 
The results showed that the median difference in CAMCOG scores from t1-t2 was significant in both 
control (z=-2.2, p=0,027) and AD participant groups (z=-3.0, p=0.003) i.e. CAMCOG scores were 
worse in AD participants but improved in control participants 1 year later.  
Table: 5.24 
Mdn (IQR) All Participants Control AD 
MMSE1 27 (22-29) 29 (28-29) 22 (18-24) 
MMSE2 27 (21-29) 28 (28-30) 20 (16-23) 
Paired Wilcox 
Signed Rank  
z (p value) 
-1.4 (0.150) -0.49 (0.63) -1.9 (0.058)  
Values are given as medians with IQR in parentheses 
 
Table: 5.25 
Mdn (IQR) All Participants Control AD 
CAMCOG1 84 (68-93) 92 (88-96) 67 (56-76) 
CAMCOG2 86 (60-94) 94 (89-94) 62 (49-73) 
Paired Wilcox 
Signed Rank 
z (p value) 
-1.3 (0.196) -2.2 (0.027**) -3.0 (0.003*) 
*significant at the 0.01 level 
** significant at the 0.05 level 
Values are given as medians with IQR in parentheses 
 
Table: 5.26 
Mdn (IQR) All Participants Control AD 
Learning 
Subscale1 
12 (8-14) 14 (13-15) 6.5 (4-10.25) 
Learning 
Subscale2 
13 (7-15) 14 (13-15) 7 (4-10.5) 
Paired Wilcox 
Signed Rank 
z (p value) 
0.25 (0.801) -1.90 (0.063)  -1.3 (0.211) 
Values are given as medians with IQR in parentheses 
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Regression analyses 
 
In table 5.27, indices summarising the variables and statistics in a simple regression model are 
shown. 
 
In AD participants only, I looked at the change in MMSE (MMSE2-MMSE1), CAMCOG (CAMCOG2-
CAMCOG1) and Learning Subscale scores (Learning2 –Learning1) as the dependent variable, and high 
baseline hcy levels as the independent variable.  
 
Results in all 3 cognitive domains were not statistically significant: high baseline hcy concentrations 
did not predict cognitive decline . 
 
Table 5.27: Simple Regression Model – high hcy concentrations and change in MMSE, change 
CAMCOG and change Learning Subscale  
 
Model 1  
Variable 
 
β 
 
p value 
 
95% CI 
Change MMSE  high hcy t1 -0.64 0.693 [-4.4,2.9] 
Change CAMCOG  high hcy t1 
 
0.122 0.459 [-4.4,9.6] 
Change Learning  high hcy t1 
 
-0.001 0.994 [-2.5,2.5] 
 
H7 was therefore not proven, high baseline hcy did not predict changes in the MMSE, CAMCOG1 and 
the Learning Subscale score in AD participants, 1 year later. The results however, showed that 
CAMCOG scores improved in controls and declined in AD partcipants 1 year after the baseline 
examination. 
 
 
5.8) Summary of results 
 
Demographic and biochemical results 
 
 AD participants were older and had fewer years of education compared with controls. 
 
 AD participants scored lower on all cognitive test scores compared with cognitively healthy 
controls. 
 
 Participants with AD had higher plasma hcy concentrations compared with participants in the 
control group. 
 
 There were a greater number of ε4 carriers in the AD group compared with the control group. 
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Results by hypothesis 
 
H1  
 Age and hcy were directly related i.e. as the participants’ ages increased, so did their plasma 
homocysteine concentrations. This relationship held true for the AD and control groups 
analysed separately. 
 
 
H2 
 
 Hcy was inversely related to vitamin B12 and folate i.e. as the vitamin B12 and folate 
concentrations decreased, hcy concentrations increased. The relationship between hcy and 
vitamin B12 held true in both AD and control groups when analysed separately. 
 
 
H3 
 
 Hcy concentrations were not associated with vascular risk factors as measured by the Co-
morbid Score. 
 
 
H4 
 
 Vitamin B12 and cognition were directly related i.e. the higher the serum vitamin B12 levels, 
the better the cognitive scores.  
 
 In a group of participants with low vitamin B12 levels (<258pmol/l), there was no association 
between vitamin B12 concentrations and cognitive impairment. 
 
 In a regression model controlling for age, both vitamin B12 concentrations and age were 
independently associated with cognitive changes. As the age of the participants increased, 
cognitive scores were lower. With increasing vitamin B12 levels, cognitive scores were higher. 
 
 
H5 
 
 Hcy concentrations were inversely related to cognitive function in all participants as well as 
AD and control groups analysed separately 
 
 The risk of cognitive impairment was 3.5x greater in participants with high hcy 
concentrations (>15mmol/l) compared to those with low hcy concentrations (<15mmol/l). 
  
 In a regression analysis, hcy concentrations were not independently associated with 
cognitive changes - age and education were significant confounding variables. The older the 
participants and the fewer years of formal education, the lower the cognitive scores. 
 
 
H6 
 
 The inverse relationship between hcy concentrations and cognition as demonstrated in H5, 
was significant in ApoE ε4 carriers but not in the ApoE ε4 non-carrier group. Age was not a 
confounding factor in this relationship. 
 
 In a regression analysis, plasma homocysteine levels did not predict cognitive scores. ApoE ε4 
carrier status and age were both independently associated with changes in cognitive scores. 
 
 
H7 
 
 In the longitudinal analysis, high baseline hcy levels did not predict cognitive decline 1 year 
later.  
 
 There were, however, significant changes in the CAMCOG scores from t1-t2 in both AD and 
control groups. Control CAMCOG scores improved and AD CAMCOG scores worsened 1 year 
later. 
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Chapter 6 
 
Discussion 
 
This study examined the associations and inter-relationships between plasma homocysteine, vitamin 
B12, folate and the ApoE genotype in a group of older South Africans with or without cognitive 
impairment (AD), who resided in the Western Cape region of South Africa. To my knowledge, this 
was the first study of its kind in a South African population and one of only a few studies (see de 
Silva et al. 2005) to examine these relationships in a developing low to middle income country  
In general, the nutritional status of persons in LMIC is believed to be poorer than that of developed 
countries, and dietary intake of vitamin B12 and folate may be less. Hence it was important to 
establish whether the same inter-relationships applied in our context, especially given the fact that 
deficiencies of vitamin B12 and folate are potentially modifiable. 
In a broad overview of the results, plasma homocysteine levels, in this sample group, were 
independently associated with age and vitamin B12 concentrations. Age, vitamin B12 levels and ApoE 
ε4 carrier status independently predicted cognitive scores. Plasma homocysteine, however, was not 
independently associated with cognition when controlling for other confounding variables, namely 
age and the level of education. Nevertheless, an inverse relationship between homocysteine and 
cognition was seen in ε4 carriers and not in ε4 non-carriers. 
Before discussing my results and hypotheses in relation to the literature, I should like to comment 
briefly on the demographics of the study population. 
 
6.1) Demographic characteristics and Baseline Cognitive Scores 
 
The Western Cape region consists largely of persons of mixed European and indigenous African 
ancestry. There were 2 main participant groups, cognitively healthy older persons (NINCDS-ADRDA 
negative) and patients with mild to moderate AD (NINCDS-ADRDA possible or probable AD). 
Participants in the AD group were slightly older than those in the control group (76.6 vs 73.2). Also, 
the AD participants had fewer years of formal education compared with controls (8 vs 14). 
Historically, older South Africans in the Western Cape born in the 1940s and 1950s, received fewer 
years of education. They left school at an early age to start work in order to supplement the income 
of large families (Callinicos 1987). A low level of education and other markers of low socio-economic 
status have been shown to be linked to AD and dementia (Stern et al.  1994, Letenneur et al. 1999, 
Ngandu et al. 2007). Furthermore, these factors also contribute to cognitive decline in older people 
(Karp et al. 1994, Evans et al. 2004).  
Age itself is the most important risk factor for the development of AD (Fratiglioni et al. 1991, 
Bachman et al. 1993, Lindsay et al. 2002). Hence it is not surprising that the AD group turned out to 
be slightly older than the control group.  
Although there were more females than males in this study, this difference was the same for both 
AD and control groups. Possible explanations for the female preponderance are the larger number 
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of older females than males in the general population and in the Western Cape in particular 
(Statistics South Africa 2011), and the greater willingness of women to participate in research studies 
compared with men (Dunn et al. 2004). 
Cognitive function scores, as measured by MMSE, CAMCOG and the Learning Subscale, were lower 
in the AD group compared with controls. This, of course, is expected as the groups were largely 
defined in terms of their cognitive function. 
 
6.2) Overall Biochemical and Genetic Characteristics 
 
 
AD and control groups differed significantly with regards to plasma homocysteine and folate 
concentrations. AD participants had higher homocysteine and lower folate levels. The difference 
between serum vitamin B12 levels in AD and control groups tended towards, but did not quite reach, 
statistical significance (p=0.053).  Many other studies have shown lower vitamin B12 levels in AD 
compared with control groups (Clarke et al. 1998, Bernard et al. 1998). There are, however, many 
potential confounding variables such as age and education, which I shall review later. 
Concerning the ApoE ε4 carrier status (homozygous and heterozygous) there were more ε4 carriers 
in the AD group compared with cognitively healthy controls (57% vs 43%). 
Possession of the ApoE ε4 allele is a well-established risk factor for late onset AD (Farrer et al. 1995). 
I have discussed the associations between AD and the ε4 allele in section 2.6.5 pg. 24. I shall further 
discuss ApoE ε4 and its inter-relationships with plasma homocysteine and cognition in H6. 
Sandholzer et al. showed that ApoE ε4 homozygotes were 3 to 5 fold more frequent in the South 
African indigenous Khoi-San community compared to a European population. Many of my 
participants are likely to have partial Khoi-San ancestry (Quintana-Murci et al. 2010). It is therefore 
not surprising that nearly half (48%) of all participants, both AD and controls, carried an ε4 allele. 
The ε4 frequency is generally believed to be higher in the indigenous African population than those 
of European descent. While not many people of the Nguni (black African) ancestry were included in 
my study, they too have allelic frequencies approaching those of the Khoi-San (Willis et al. 2003, 
Joska et al. 2010). 
There was a two-fold increased risk of AD in ε4 carriers compared with ε4 non-carriers. One possible 
biological mechanism underlying the increased susceptibility to AD in ApoE ε4 carriers include less 
efficient clearance of amyloid from the brain parenchyma (Strittmatter et al. 1993). Additionally, the 
ApoE ε4 allele is associated with impaired neurite growth, cytoskeletal instability and mitochondrial 
dysfunction in neurones (Nathan et al. 1994 and 1995). 
The results of this study, if extrapolated to the rest of the South African population, suggest that we 
will be faced with a major epidemic of AD in the future as life expectancy increases and the 
indigenous population with a high ε4 carrier frequency ages. 
I shall now discuss the results with regards to the specific hypotheses (H1-H7). 
 
 
 
100 
 
6.3) H1:  Age and plasma homocysteine levels were directly related i.e. as the participants’ 
ages increased, so did their plasma homocysteine concentrations. 
 
My results were consistent with findings from European and North American studies. Most of these 
studies describe a positive correlation between advancing age and plasma homocysteine 
concentrations, independent of vitamin status and vascular risk factors (Selhub et al. 1993, Nygard 
et al. 1998).  
I showed an independent association between age and homocysteine levels unrelated to vitamin B12 
and folate status. This relationship was significant in all participants as well as in AD and control 
groups analysed separately. Older age was associated with higher homocysteine concentrations not 
only in patients with AD, but also in cognitively healthy older persons. It is possible that additional 
age-related factors such as deteriorating renal function and the presence of vascular disease, could 
explain the relationship between age and homocysteine.  
Serum creatinine has been shown to be a strong determinant of plasma homocysteine 
concentrations in general (Bostom et al. 1999, Wollensen et al. 1999) and in older persons 
particularly (Brattstrom et al. 1994, Norlund et al. 1998, Chen et al. 2013). I had serum creatinine 
measurements for all the participants. Thus, as part of a post-hoc analysis, I analysed the 
relationship between serum creatinine and plasma homocysteine. They were, in fact, strongly 
correlated i.e. as the serum creatinine levels increased so did the plasma homocysteine 
concentrations (rs=0.587, p=<0.001).  
Clinically, there were no obvious nutritional deficiencies or malabsorption syndromes present in the 
participants. However, subclinical or subtle B12 deficiencies, other dietary deficiencies and 
malabsorption syndromes, many of which may also be age-related, cannot be excluded. Other 
lifestyle and environmental factors such as smoking (Targer et al. 2000), alcohol consumption 
(Sakuta et al. 2005), coffee consumption (Temple et al. 2000), drug interactions (Sachdev et al. 2004) 
and decreased exercise and stress, may contribute to elevated homocysteine concentrations 
although little is known about their associations with plasma  homocysteine levels in older persons. 
A larger epidemiological study amongst older South Africans would be useful to determine whether 
other factors mentioned above contribute to elevated plasma homocysteine levels with advancing 
age. 
In summary, the findings from my study confirmed the independent association between age and 
plasma homocysteine previously reported in international studies. Declining renal function may 
partly explain this association. 
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6.4) H2: Plasma homocysteine concentrations were inversely related to vitamin B12 and 
folate levels i.e. as the vitamin B12 and folate concentrations decreased, plasma 
homocysteine concentrations increased. 
  
The inverse relationship between vitamin B12 and homocysteine has been well documented i.e. low 
vitamin B12 levels are linked to higher plasma homocysteine concentrations (Stabler et al. 1988, 
Selhub et al. 1993, Ubbink et al. 1993, McCaddon et al. 1998). My findings are consistent with those 
reported in the literature.  Homocysteine, along  with measurements of other biological compounds 
such as methylmalonic acid (MMA) and holotranscobalamin (holoTC), probably better reflect vitamin 
B12 status than circulating blood plasma vitamin B12 concentrations (Clarke et al. 2004, Miller et al. 
2006). 
The relationship between vitamin B12 and homocysteine was stronger in the AD group compared 
with cognitively healthy controls and the median homocysteine concentrations were higher in the 
AD group compared with the controls. This suggests that the association between vitamin B12 and 
homocysteine is not linear (figure a) but exponential (figure b) i.e. homocysteine levels rise more 
rapidly when vitamin B12 levels are in the lower range.  A study by Vogiatzoglou et al.  in 2009 
supports this idea. 
                                            Figure a                                                                          Figure b 
 
 
 
 
                                               
                                              Vitamin B12                                                                                                  Vitamin B12 
The fact that most participants had folate levels in the normal to high range (12 - >45.5nmol/l), 
probably reflects the fact that folic acid fortification of cereals and wheat in South Africa is 
mandatory. This was introduced in 2003. When the group median values were compared with the 
defined National Health Laboratory Service (NHLS) normal reference ranges there were no 
participants with low folate (<5 nmol) levels. Additionally, the widespread use of multi-vitamin 
supplementation by older people is likely to contribute to the excessively high folate values 
measured (NFCS-2005).  
In a multiple regression model, vitamin B12 levels, but not plasma folate, independently predicted 
changes in plasma homocysteine concentrations. This inter-relationship can be explained by the 
closely linked metabolism between vitamin B12 and plasma homocysteine (see figure 6.1). 
Remethylation of homocysteine to methionine (which eliminates excessive homocysteine), is 
catalysed by methionine synthase (MS), a vitamin B12 - dependent enzyme. Thus, vitamin B12 
deficiency, occurring through reduced dietary intake would result in reduced MS activity and 
hyperhomocysteinaemia. Dietary lack and reduced absorption of B12 could well apply to older 
persons in our study. 
Vitamin B12, folate and their associations with cognitive function are discussed later on in H4 
              hcy            hcy 
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Figure 6.1: The Metabolism of Homocysteine 
From: Doshi et al. 1999 
 
 
 
 
6.5) H3: Plasma homocysteine concentrations were not associated with vascular risk 
factors as measured by the Co-morbid Score. 
 
The association between elevated homocysteine levels and vascular disease has been well 
documented in the literature based on studies conducted mainly in Europe and North America. 
Plasma homocysteine is an independent risk factor for atherosclerosis as well as cardiovascular and 
cerebrovascular disease (Clarke et al. 1991; den Heijer et al. 1996; Selhub et al. 1995; Ueland et al. 
2000). Certain vascular risk factors, such as hypertension and cigarette smoking, may work 
synergistically with high homocysteine levels to potentiate vascular disease (Graham et al. 2002, 
O’Callaghan et al. 2002). Independent associations between systolic blood pressure and 
homocysteine levels have also been reported (Sutton-Tyrell et al. 1997, Budge et al. 2002). 
In this study, I hypothesised that higher plasma homocysteine levels would be associated with 
increasing numbers of vascular risk factors. There was, however, no significant relationship between 
plasma homocysteine and vascular risk factors as measured by the Co-morbid score. Additionally, 
there was no significant relationship between the Co-morbid score and cognition as measured by 
MMSE, CAMCOG and the Learning Subscale (post-hoc analysis MMSE p=0.22, CAMCOG p=0.109, 
Learning Subscale p=0.082). 
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Possible reasons for the lack of association are as follows: 
 
i. The Co-morbid Score was based on previous diagnoses from clinical records. I did not apply 
strict criteria for the diagnosis of hypertension, Type 2 Diabetes Mellitus and 
hypercholesterolaemia. Therefore, this was a crude measure of vascular risk factors. 
 
ii. The score was based on the presence or absence of risk factors. It did not account for the 
degree of severity or participant compliance with medication. For example, 2 participants 
could be assigned the same score rating with completely different severities or control of 
the vascular risks. For example, one participant might have a blood pressure (BP) of 
220/110, a plasma glucose level of 15mmol/l, a cholesterol levels of 9mmol/l and smoke 20 
cigarettes/day. Another participant might have had a marginally raised BP of 150/95, a 
plasma glucose of 8mmol/l, a cholesterol level of 7mmol/l and smoke 10 cigarettes/day. 
Both would have been assigned the same Co-morbid score.  
 
The above hypotheses evaluated the associations between plasma homocysteine and its various 
determinants in this sample population. In a single stepwise regression model, vitamin B12, age and 
serum creatinine levels independently predicted plasma homocysteine levels. These findings are 
consistent with the published literature (Selhub et al. 1993, Seshadri et al. 2002). Our failure to find 
an association between plasma homocysteine and vascular risk factors could be due to the lack of 
refinement of the Co-morbid score.  
Large epidemiological studies with strict diagnostic criteria and measurements of severity would be 
more useful. In a future study we should attempt to assess the extent of cerebrovascular disease, 
both overt and subclinical, by quantifying the degree of white matter changes using MRI scans.  
 
6.6) H4: Vitamin B12 and folate are directly related to cognition. 
        Serum vitamin B12 levels and age independently predicted cognitive scores. 
 
Vitamin B12 
 
In this study vitamin B12 was positively correlated with cognition as measured by MMSE, CAMCOG 
and the Learning Subscale scores in all study participants. These results were broadly in agreement 
with the majority of cross-sectional studies which demonstrated an association between low vitamin 
B12 and cognition in older persons (Goodwin et al. 1983, Bernard et al. 1998, Lindeman et al. 2000). 
These authors agree that low vitamin B12 and folate levels are associated with poorer cognitive 
function in older persons.  
In my study the median vitamin B12 concentration in AD participants was lower compared with 
controls (317 vs 414 pmol/l) but both median values were normal by South African NHLS laboratory 
standards. In a categorical analysis, there was no association between vitamin B12 levels and 
cognitive impairment. In fact, there were very few people in this sample with traditionally defined 
low vitamin B12 levels (<148 pmol/) and subclinical vitamin B12 deficiency (<258 pmol/). Thus, the 
number of vitamin B12 deficient persons may have been too small to demonstrate an association 
with cognition categorically. Additionally, it is also possible that serum vitamin B12 measurements 
were not truly reflective of the intracellular vitamin B12 status in my study participants. Other 
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markers of low vitamin B12 such as elevated plasma homocysteine, methylmalonic acid (MMA) and 
holoTC measurements could more accurately reflect low vitamin B12 status (Clarke et al. 2004, Miller 
et al. 2006, Obeid et al. 2007).  
In a post-hoc categorical analysis, using a median split of vitamin B12 concentrations, a contingency 
table analysis showed that vitamin B12 levels <350 pmol were more closely related to cognition than 
the previous categorical analysis using a vitamin B12 cut-off <258pmol/l (p= 0.14 vs p= 0=0.074). This 
supports the supposition that larger numbers could improve the statistical significance of the result.   
In a multiple regression analysis, vitamin B12 levels and age both independently predicted changes in 
cognitive scores.  
Biologically, cognitive impairment as a result of low vitamin B12 levels could be mediated by the 
effects of elevated plasma homocysteine or MMA which are both neurotoxic (Carmel 1996).  They 
have both also been associated with brain atrophy and white matter damage (Vogiatzoglou et al. 
2008, Smith and Refsum 2009). Clinical intervention trials would be needed to determine whether 
vitamin B12 supplementation improves the signs and symptoms in early AD. Future studies with more 
accurate measurements of vitamin B12 status (holoTc and MMA) could indicate that the traditional 
vitamin B12 cut-off value, used by South African laboratories, are too low. Treatment with vitamin B12 
at a higher level than is currently indicated (up to 300pmol/l) may slow the neurological effects of 
vitamin B12 deficiency including brain atrophy (Smith et al. 2010).  
 
Folate     
 
Folate was inversely related to plasma homocysteine concentrations in all participants as well as in 
the AD and control group. This is in keeping with the literature (Clarke et al. 1998, Seshadri et al. 
2002). Folate concentrations were related to the CAMCOG and Learning Subscale scores but not to 
the MMSE score. Median folate concentrations were lower in the AD group compared with controls 
(25 vs 36 nmol/l). These findings are in keeping with studies that demonstrate that low folate levels 
are associated with poorer cognition (Clarke et al. 1998, Ramos et al. 2005, Ravaglia et al. 2005, Kim 
et al. 2008). 
Biologically, low folate levels could cause cognitive impairment through 1) the toxic effects of 
elevated plasma homocysteine concentrations, 2) lack of folate (a precursor of purines and 
pyrimidine bases) leads to defective DNA and neuronal death (Kruman et al. 2000). Deficiency of 
folate is also linked to cerebral atrophy through vascular and nonvascular mechanisms such as 
altered neurotransmitter metabolism (Snowdon et al. 2000). 
In summary, based on my findings and recommendations from overseas studies, vitamin B12 and 
folate are beneficial to cognitive health. Thus it may be worthwhile supplementing vitamin B12 
especially in older people with and without symptoms of deficiency. This is because, 1) older persons 
are more susceptible to subclinical deficiency and 2) South African foods are fortified with folic acid. 
High folate concentrations could potentially mask underlying vitamin B12 deficiency and potentiate 
cognitive impairment (Smith et al. 2009 and 2012, Selhub et al. 2009). 
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6.7) H5: Plasma homocysteine concentrations were inversely related to cognitive function. 
However they did not predict cognitive test scores in a regression model when controlling 
for age. 
 
 
The association between elevated homocysteine levels and Alzheimer’s disease established in the 
1990s originated from studies which demonstrated an association between plasma homocysteine 
concentrations and atherosclerosis and cerebrovascular disease (Perry et al. 1995; Bots et al. 1997, 
Seshadri et al. 2008). Vascular risk factors are also a risk factor for Alzheimer’s disease and, by 
association it is therefore plausible that homocysteine may be a risk factor for Alzheimer’s disease.  
This hypothesis has been evaluated at length over the last decade in retrospective and prospective 
studies (Clarke et al. 1998, McCaddon et al. 1998, Seshadri et al. 2002, Ravaglia et al. 2005).  
The following facts are generally accepted regarding plasma homocysteine concentrations: 
 
i. Plasma homocysteine levels increase with age (H1). 
ii. Plasma homocysteine levels are higher in AD patients compared with controls. 
iii. Plasma homocysteine is an independent risk factor for AD (controlling for cofounders of age, 
sex, education and vascular disease). 
iv. Elevated plasma homocysteine levels at baseline predict faster cognitive decline. 
 
In keeping with the findings of studies abroad, this study, in a continuous analysis, demonstrated an 
inverse association between plasma homocysteine concentrations and cognition as measured by the 
MMSE, CAMCOG and Learning Subscale scores. There were more AD participants with higher 
homocysteine concentrations compared to cognitively healthy controls (12 vs 5). The odds of having 
AD in individuals with high homocysteine concentrations was 3.5-fold greater compared with low 
homocysteine levels (<15mmol/l).  These results were in keeping with the majority of case-control 
studies (Clarke et al. 1998, McCaddon et al. 1998, Selley et al. 2002, Gallucci et al. 2004, Linnebank 
et al. 2010). 
I should point out that the cut-off value used to split plasma homocysteine concentrations into high 
and low groups in the categorical analysis was based on the reference ranges used by the South 
African “Path Care” laboratory. The laboratory based these cut-offs on the normal distribution of a 
European population (Fiekerstrand et al. 1993, Clarke et al. 1998). It has been suggested that a 
plasma homocysteine reference range should be established by individual laboratories to reflect 
their specific regional population with specific limits set for children, adults and the elderly (Refsum 
et al. 2004). Additionally, South Africa has mandatory folate fortification and therefore the upper 
limit of the plasma homocysteine reference range would generally be lower; in some cases up to 
25% lower than that of a non-fortified population (Jacques et al. 1999, Refsum et al. 2004). The 
median homocysteine concentration in my study sample was 10.2mmol/l in all participants, 
10.6mmol/ in the AD group and 9.3 mmol/l in controls. In the AD group, I would have expected a 
higher median plasma homocysteine concentration based on literature findings. However, this value 
may still represent a mild-moderately elevated concentration in the South African population.   
I used regression models to determine whether the relationship between homocysteine and 
cognition still held true if I controlled for possible confounders, viz. age and education. (Age and 
education were both related to cognitive function). Plasma homocysteine concentrations did not 
predict changes in MMSE, CAMCOG and the Learning Subscale scores when controlling for age and 
years of education. However, in a post hoc analysis, high levels of homocysteine (>15 mmol/l) did 
predict changes in the CAMCOG and Learning Subscale scores. 
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This could be explained in two ways. Firstly, the CAMCOG and Learning Subscale scores are more 
sensitive tools for detecting early changes in cognition compared with the MMSE score (Hobson et 
al. 2012, Clarke CM et al. 1999).Secondly, the result again supports the hypothesis that the inverse 
association between plasma homocysteine and cognition is not linear (figure c) but rather 
exponential (figure d) i.e. cognition declines more rapidly with elevated plasma homocysteine 
concentrations. 
 
 
                                  Figure c                                                             Figure d 
 
 
 
 
 
 
                                          hcy                                                                                                     hcy 
 
 
 
 
6.8) H6: The relationship between plasma homocysteine concentrations and cognition was 
significant in ε4 carriers but not in the ε4 non-carrier group.  
 
The modifying effects of ApoE ε4 status on the relationship between homocysteine and cognition 
has been researched but has not, in my opinion, been adequately explained. A small number of 
studies have examined the effects of ApoE ε4 status on the relationships between 1) vitamin B12 and 
cognition and 2) plasma homocysteine and cognition (Brown et al. 2011, Feng et al. 2009, 
Vogiatzoglou et al. 2013). The results of these studies indicate that the ApoE ε4 carrier status 
strengthens the associations between vitamin B12, plasma homocysteine and cognition (Elias et al. 
2007, Vogiatzoglou et al. 2013). 
In this study sample, without controlling for covariate factors, the inverse relationship between 
plasma homocysteine and cognition was accentuated in ApoE ε4 carriers relative to the same 
correlation in all participants (H5). The relationship between plasma homocysteine and cognition, in 
fact, did not exist in ApoE ε4 non-carriers. This result is in keeping with findings by Elias et al. In their 
study, they demonstrated a higher magnitude of association between plasma homocysteine and 
cognitive performance within ApoE ε4 carriers relative to ApoE ε4 non-carriers.  When controlling 
for covariate factors, they observed no significant relationship between cognition and plasma 
homocysteine in ApoE ε4 non-carriers (Elias et al. 2007).  
Although the biological mechanisms by which the ε4 allele strengthens the relationship between 
plasma homocysteine and cognition are not clear, it has been suggested that environmental factors 
could perpetuate cognitive impairment in those who are genetically predisposed to developing the 
disease. Individuals with the ApoE ε4 genotype may be more vulnerable to other risk factors for 
cognitive impairment such as plasma homocysteine (Kivipelto et al. 2008). Biologically, I 
hypothesized that the stronger relationship between plasma homocysteine and cognition in ε4 
carriers could be mediated by abnormal Aβ metabolism.  ApoE ε4 carriers have defective 
cognition cognition
n 
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mechanisms of Aβ clearance (Holtzman et al. 2000) and plasma homocysteine concentrations could 
increase amyloid deposition in the brain and also render neurones more susceptible to damage by 
Aβ peptides (Obeid et al. 2006; Stanger et al. 2009, Ho et al. 2001). Thus, the ApoE ε4 genetic 
predisposition coupled with the neurotoxic effects of plasma homocysteine, could result in increased 
levels of amyloid in the brain and more damage to neurones relative to ε4 non-carriers. 
It has also been demonstrated that the ApoE ε4 status strengthens the relationship between vitamin 
B12 and cognition (Vogiatzoglou et al. 2013). In my study, post-hoc analyses showed that ApoE ε4 
allelic status did not strengthen the relationship between vitamin B12 and cognition.  In fact, there 
was no relationship between vitamin B12 and cognition when analysed in ε4 carriers and ε4 non-
carriers separately. 
It would be promising if a risk factor such as plasma homocysteine could be modified to reduce the 
adverse effects on cognition in individuals with a genetic predisposition to AD. This would be 
especially important in South Africa given the high ApoE ε4 allelic frequency in the indigenous 
population. 
 
6.9) H7: high baseline plasma homocysteine levels did not predict cognitive decline 1 year    
later.  
 
In this study we did not show that high baseline plasma homocysteine levels predicted cognitive 
decline 1 year after the initial assessment. However, the median CAMCOG scores in both AD and 
control groups were significantly different between the baseline and follow-up time point. In the AD 
group, scores were significantly lower 1 year later compared to the control group whose scores 
improved over the same period. 
Studies reporting cognitive decline with high baseline homocysteine concentrations had long follow-
up periods or have followed a cohort of patients with rapidly declining cognitive scores. Seshadri and 
Zylberstein et al.  had followed their dementia-free cohort over a period of 8 and 35 years 
respectively, whilst the studies of Annerbo and Oulhaj et al. followed MCI participants and their 
conversion to Alzheimer’s disease over 6 and 9.5 years respectively (Seshadri et al. 2002, Zylberstein 
et al. 2011, Annerbo et al. 2006, Oulhaj et al. 2010). Our study looked at potential cognitive decline 1 
year later which was most likely too short to demonstrate any significant change. 
The MMSE, though widely used, is an insensitive measure of early cognitive changes and is of limited 
value in measuring the progression of Alzheimer’s’ Disease in less than 3 years due to the individual 
variability of score (Clarke CM et al. 1999). The CAMCOG scores decreased in participants with AD 
over a period of 1 year and improved in cognitively healthy controls. This was expected for the AD 
participants and could be explained by practice/learning effects in the controls. 
Hobson et al. demonstrated that the CAMCOG was more sensitive in detecting cognitive impairment 
compared with the MMSE score (Hobson et al. 1999). Another study showed that the orientation 
and memory (learning) subscale of the CAMCOG was the best predictor of conversion to AD, but that 
global MMSE and CAMCOG scores were poor predictors (Conde-Sala et al. 2012). 
In summary, the follow-up period was probably too short to adequately test H7. 
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Study limitations and recommendations for future research 
 
There are several factors which could account for the discrepancies found in this study relative to 
overseas literature findings.  
I. This study was an observational case-control study. Although this type of study is less 
expensive and requires less time compared with longitudinal cohort studies, it is difficult to 
disentangle cause and effect in the population studied. I was not able to determine whether 
participants with AD developed low vitamin B12 and high homocysteine levels as a 
consequence of poor dietary intake, which is common in older people, or whether these 
abnormalities preceded the onset of the disease. The literature indicates that low vitamin 
B12 and elevated plasma homocysteine levels are, in fact, risk factors for AD. They therefore 
precede the advent of the disease. 
 
II. This was not a large epidemiological study, but rather a small sample of participants in the 
Western Cape. The results therefore reflect demographic characteristics and associations 
specific to this region and are not necessarily representative of the South African population. 
 
III. As indicated before, I used the most inexpensive and readily available methods for assessing 
vitamin B12 and plasma homocysteine concentrations. Ideally, however, more sensitive 
methods of quantifying intracellular vitamin B12 levels (holoTC, MMA) may have generated 
more significant results. In addition, it is recommended that fasting or meal-standardised 
measurements for plasma homocysteine should be used, as protein intake has been shown 
to cause variations in the plasma homocysteine concentrations on a day-to-day basis (Thirup 
et al. 1999). I used non-fasting plasma homocysteine concentrations in this study. A more 
standardised protocol for blood taking, following a fasting period, may have produced more 
significant findings.  
 
IV. The Co-morbid score was a crude measure of vascular disease. An interesting dimension to 
this study would be to relate plasma homocysteine levels to cerebrovascular disease by 
quantifying the extent of WMHs in the brain on MRI scans. 
 
V. The longitudinal part of this study was too short to observe any change in cognitive scores. It 
also suffered from a high attrition rate. The solution to this would have been to have larger 
numbers in the beginning of the study and a longer follow-up period.  
 
Despite these shortcomings, this study is important because it is the first to examine the 
relationships between plasma homocysteine, vitamin B12, folate, ApoE ε4 status and Alzheimer’s 
disease in Southern Africa. The results of this study have largely agreed with the literature findings in 
European and North American studies.  
In South Africa, we have the unique combination of a high background ApoE ε4 allelic frequency as 
well as an ageing population with a generally poor nutritional status. For all these reasons, it would 
be helpful for both our and the worlds ageing population, to further explore the risk factors for 
Alzheimer’s disease and especially the inter-relationships between vitamin B12, folate, the ApoE 
gene, plasma homocysteine and cognitive function. 
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A further study with larger participant numbers and a sample more representative of the diverse 
ancestral background of the South African population, would better be able to describe Alzheimer’s 
disease and its associations and risk factors in our context. 
 
Conclusion 
 
I hope my study, despite its limitations, will serve as the basis for continued future research on 
Alzheimer’s disease in South Africa. I should like to continue to be involved in work of this nature.  
In addition to poor access to health care facilities, there are still strong social stigmata regarding 
Alzheimer’s disease. The latter are especially pronounced in traditional communities. There is a lack 
of knowledge about the disease not only amongst communities and the families and carers with 
Alzheimer’s disease, but also amongst health professionals. The disease is under-reported and 
under-diagnosed in South Africa because of these factors and also because the burden of chronic 
infections related to HIV has received a greater health priority.   
While we cannot change the fact that the population will age and that the genetic predisposition to 
Alzheimer’s disease is non-modifiable, it is important for South Africans to be aware of potentially 
modifiable risk factors for cognitive impairment.  Although I am aware that there still is a long way to 
go in identifying methods that could modify disease outcome or slow cognitive decline, I hope that 
my study findings will assist in this process. 
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Appendix 
 
Clinical Diagnostic Criteria 
Appendix A 
NINCDS / ADRDA (Alzheimer’s disease) 
McKhann G et al. Neurology 1984; 34: 939-944 
 
0. Negative 
 
1. Possible 
 
I. Presence of a dementia syndrome, in absence of other neurological, psychiatric or systemic 
disorders capable of causing dementia, but with atypical features, such as variations in the 
onset, presentation or clinical course of the illness. 
 
II. Presence of a second systemic disease or brain disorder sufficient to produce dementia, but 
not considered to be the cause of the dementia. 
 
III. Single, gradually progressive, severe cognitive deficit (e.g. Worsening amnestic syndrome), in 
the absence of another identifiable cause. 
 
 
2. Probable  
 
I. Dementia, established by history & clinical examination, and documented with, or confirmed 
by, cognitive or neuropsychological tests e.g. MMSE (<23), CAMCOG (<80). 
II. Deficits in 2 or more areas of cognition. 
 
III. Progressive worsening of memory and other cognitive functions. 
 
IV. No disturbance of consciousness. 
 
V. Age of onset > 40; usually > 65. 
 
VI. Absence of systemic disorders or other brain diseases [or psychiatric disorders] that could in 
themselves account for the progressive deficits in memory & cognition. 
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3. Definite 
 
I. Probable AD on clinical criteria. 
 
II. Histopathological evidence (biopsy, autopsy). 
 
Supportive evidence for the diagnosis of Probable AD: 
I. Progressive deterioration of specific cognitive functions such as language (aphasia), motor 
skills (apraxia), and perception (agnosia); 
II. impaired activities of daily living and altered patterns of behaviour; 
 
III. family history of similar disorders, particularly if confirmed neuropathologically; and 
 
IV. laboratory results of: 
a) normal lumbar puncture as evaluated by standard techniques; 
 
b) normal pattern or non-specific change in EEG, such as increased slow wave activity, and 
 
c) evidence of cerebral atrophy on CT with progression documented by serial observation. 
 
 
Clinical features consistent with the diagnosis of Probable AD: 
 
I. Plateaus in the course of progression of the illness. 
 
II. Associated symptoms of depression, insomnia, incontinence, delusions, illusions, 
hallucinations, catastrophic verbal, emotional or physical outbursts, sexual disorders and 
weight loss. 
 
III. Other neurological abnormalities in some patients, especially those with more advanced 
disease, including motor signs such as increased motor tone, myoclonus or a gait disorder. 
 
 
IV. Seizures in advanced disease. 
 
V. CT normal for age. 
 
Features that make the diagnosis of Probable AD uncertain or unlikely include: 
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I. Sudden apoplectic onset. 
 
II. Focal neurological signs such as hemiparesis, sensory loss, visual field deficits, and 
incoordination early in the course of the illness. 
 
 
III. Seizures or gait disturbances at the onset or very early in the course of the illness. 
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Appendix B 
DSM-IV diagnostic criteria for dementia of the Alzheimer’s type  
 
Diagnostic and Statistical Manual of Mental Disorders, 4th ed., American Psychiatric Association, 
1994; p142. 
 
A. The development of multiple cognitive deficits manifest by both 
 (1) memory impairment  
AND 
 (2) one (or more) of the following cognitive disturbances: 
 
(a) aphasia (language disturbance) 
(b) apraxia (impaired ability to carry out motor activities despite intact motor function) 
(c) agnosia (failure to recognize objects despite intact sensory function) 
(d) disturbance in executive functioning (i.e. planning, organization, sequencing, abstracting). 
 
B. The cognitive deficits in criteria A1 and A2 each cause significant impairment in social or 
occupational functioning and represent a significant decline from a previous level of 
functioning. 
C. The deficits do not occur exclusively during the course of a delirium. 
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Appendix C 
Mild Cognitive Impairment (MCI) 
 
Petersen RC et al. Neurology 2001; 56: 1133-42 
I. Memory complaint, preferably corroborated by an informant. 
 
II. Objective memory impairment. 
 
III. Normal general cognitive functioning. 
 
IV. Intact activities of daily living. 
 
V. Not demented. 
 
 
Appendix D 
 
Deterioration Cognitive Observee (DECO) 
 
Ritchie et al. 1992 
  
We would like you to tell us how your relative was a year ago. The following questions ask about a number of 
everyday situations. We would like you to tell us whether in these situations he/she is doing about the same, 
not as well or much worse, than a year ago. Place a tick in the relevant column to show your response.  
 
 Better or 
about the 
same 
Not as well Much 
worse 
1. Does he/she remember as well as before which day of the week and which month it is?    
2. When he/she goes out of the house, does he/she know her way as well as before?    
3. Have there been changes in his/her ability to remember his/her own address or 
telephone number 
   
4. In the house, does he/she remember as well as before where things are usually kept?    
5. And when an object isn’t in its usual place, is he/she capable of finding it again?    
6. In comparison with a year ago, how well is he/she able to use household appliances 
(washing machine, etc….)? 
   
7. Has his/her ability to dress or undress changed at all?    
8. How well does he/she manage his/her money, for example, doing the shopping?    
9. Apart from difficulties due to physical problems, has there been a reduction in his/her 
activity level? 
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10. How well can he/she follow a story on television, in a book or told by someone?    
11. And writing letters for business or to friends; does he/she do this as well as a year 
ago? 
   
12. How well does he/she recall a conversation you had with him/her a few days ago? Has 
this changed over the past year? 
   
13. And if you remind him/her of this conversation, does he/she still have difficulty 
remembering it in comparison to a year ago? 
   
14. Does he/she forget what he/she wanted to say in the middle of a conversation? Has 
this changed over the past year? 
   
15. In a conversation, does he/she sometimes have difficulty finding the right word?    
16. In comparison with a year ago, how well does he/she recognize the faces of people 
he/she knows well? 
   
17. And how well does he/she remember the names of these people?    
18. In comparison with a year ago, how well does he/she remember other details 
concerning people he/she knows well; where they live, what they do? 
   
19. Over the past year, have there been changes in his/her ability to remember what has 
happened recently? 
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Appendix E 
 
Geriatric Depression Scale (GDS) 
 
Brink et al. 1982 
 
 
Choose the best answer for how you have felt over the past week: 
1. Are you basically satisfied with your life?      YES / NO 
2. Have you dropped many of your activities and interests?     YES / NO 
3. Do you feel that your life is empty?       YES / NO  
4. Do you often get bored?        YES / NO 
5. Are you in good spirits most of the time?       YES / NO 
6. Are you afraid that something bad is going to happen to you?    YES / NO 
7. Do you feel happy most of the time?       YES / NO 
8. Do you often feel helpless?        YES / NO 
9. Do you prefer to stay at home, rather than going out and doing new things?   YES / NO 
10. Do you feel you have more problems with memory than most?    YES / NO 
11. Do you think it is wonderful to be alive now?      YES / NO 
12. Do you feel pretty worthless the way you are now?     YES / NO 
13. Do you feel full of energy?        YES / NO 
14. Do you feel that your situation is hopeless?      YES / NO 
15. Do you think that most people are better off than you are?    YES / NO 
 
Scoring System: Yes=1, No=0 
GDS >7 = depression 
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Appendix F 
 
The Bristol Activities of Daily Living Scale (BADLS) 
 
Buck et al. 1996 
 
This questionnaire is designed to reveal the everyday ability of people who have memory difficulties 
of one form or another. For each activity (Nos. 1-20), statements a-e refer to a different level of 
ability. Thinking of the last 2 weeks, tick the box that represents your relative's/friend's ability. 
Only 1 box should be ticked for each activity. 
(If in doubt about which box to tick, choose the level of ability which represents their average 
performance over the last 2 weeks). 
 
1. FOOD  
 a. Selects and prepares food as required      [    ]  
 b. Able to prepare food if ingredients set out      [    ]  
 c. Can prepare food if prompted step by step      [    ]  
 d. Unable to prepare food even with         
      prompting and supervision                     [    ] 
 e. Not applicable         [    ]  
 
2. EATING  
 a. Eats appropriately using correct cutlery      [    ] 
 b. Eats appropriately if food made manageable and/or uses spoon               [    ] 
 c. Uses fingers to eat food        [    ] 
 d. Needs to be fed         [    ] 
 e. Not applicable         [    ] 
 
 
3. DRINK 
 a. Selects and prepares drinks as required     [    ] 
 b. Can prepare drinks if ingredients left available    [    ] 
 c. Can prepare drinks if prompted step by step      [    ] 
 d. Unable to make a drink even with prompting and supervision   [    ] 
 e. Not applicable         [    ] 
 
 
4. DRINKING 
 a. Drinks appropriately         [    ] 
 b. Drinks appropriately with aids, beaker/straw etc.     [    ] 
 c. Does not drink appropriately even with aids but attempts to    [    ] 
 d. Has to have drinks administered (fed)      [    ] 
 e. Not applicable         [    ] 
 
5. DRESSING 
 a. Selects appropriate clothing and dresses self     [    ] 
 b. Puts clothes on in wrong order and/or back to front  
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  and/or dirty clothing       [    ] 
 c. Unable to dress self but moves limbs to assist     [    ] 
 d. Unable to assist and requires total dressing     [    ] 
 e. Not applicable        [    ] 
 
6. HYGIENE 
 a. Washes regularly and independently      [    ] 
 b. Can wash self if given soap, flannel, towel,     [    ] 
 c. Can wash self if prompted and supervised     [    ] 
 d. Unable to wash self and needs full assistance     [    ] 
 e. Not applicable        [    ] 
 
7. TEETH 
 a. Cleans own teeth/dentures regularly and independently    [    ] 
 b. Cleans teeth/dentures if given appropriate items     [    ] 
 c. Requires some assistance, toothpaste on brush,brush to mouth, etc.   [    ] 
 d. Full assistance given         [    ] 
 e. Not applicable          [    ] 
 
8. BATH/SHOWER 
 a. Bathes regularly and independently       [    ] 
 b. Needs bath to be drawn/shower turned on but  
  washes independently         [    ] 
 c. Needs supervision and prompting to wash      [    ] 
 d. Totally dependent, needs full assistance       [    ] 
 e. Not applicable          [    ] 
 
 
9. TOILET/COMMODE 
 a. Uses toilet appropriately when required      [    ] 
 b. Needs to be taken to the toilet and given assistance      [    ] 
 c. Incontinent of urine or faeces        [    ] 
 d. Incontinent of urine and faeces        [    ] 
 e. Not applicable         [    ] 
  
 
10. TRANSFERS 
 a. Can get in/out of chair unaided       [    ] 
 b. Can get into a chair but needs help to get out      [    ] 
 c. Needs help getting in and out of a chair      [    ] 
 d. Totally dependent on being put into and lifted from chair     [    ] 
 e. Not applicable          [    ] 
 
11. MOBILITY 
 a. Walks independently        [    ] 
 b. Walks with assistance, i.e. furniture, arm for support     [    ] 
 c. Uses aids to mobilize, i.e. frame, sticks etc.     [    ] 
 d. Unable to walk         [    ] 
 e. Not applicable         [    ] 
 
12. ORIENTATION—TIME 
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 a. Fully orientated to time/day/date etc.      [    ] 
 b. Unaware of time/day etc but seems unconcerned     [    ] 
 c. Repeatedly asks the time/day/date      [    ] 
 d. Mixes up night and day       [    ] 
 e. Not applicable        [    ] 
 
13.  ORIENTATION—SPACE 
 a. Fully orientated to surroundings       [    ] 
 b. Orientated to familiar surroundings only      [    ] 
 c. Gets lost in home, needs reminding where bathroom is, etc.   [    ] 
 d. Does not recognize home as own and attempts to leave    [    ] 
 e. Not applicable         [    ] 
 
14. COMMUNICATION  
 a. Able to hold appropriate conversation      [    ] 
 b. Shows understanding and attempts to respond  
      verbally with gestures                       [    ] 
 c. Can make self understood but difficulty understanding others   [    ] 
 d. Does not respond to or communicate with others     [    ] 
 e. Not applicable                                                                                                                                [    ] 
 
15. TELEPHONE 
 a. Uses telephone appropriately, including obtaining correct number  [    ] 
 b. Uses telephone if number given verbally/visually or predialled  [    ] 
 c. Answers telephone but does not make calls     [    ] 
 d. Unable/unwilling to use telephone at all     [    ] 
 e. Not applicable         [    ] 
 
16. HOUSEWORK/GARDENING 
 a. Able to do housework/gardening to previous standard   [    ] 
 b. Able to do housework/gardening but not to previous standard  [    ] 
 c. Limited participation even with a lot of supervision    [    ] 
 d. Unwilling/unable to participate in previous activities    [    ] 
 e. Not applicable        [    ] 
 
17. SHOPPING 
 a. Shops to previous standard       [    ] 
 b. Only able to shop for 1 or 2 items with or without a list   [    ] 
 c. Unable to shop alone, but participates when accompanied   [    ] 
 d. Unable to participate in shopping even when accompanied   [    ] 
 e. Not applicable        [    ] 
 
18. FINANCES 
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 a. Responsible for own finances at previous level    [    ] 
 b. Unable to write cheque but can sign name and recognizes  
                   money values        [    ] 
 c. Can sign name but unable to recognize money values    [    ] 
 d. Unable to sign name or recognize money values    [    ] 
 e. Not applicable            [    ] 
 
19. GAMES/HOBBIES 
 a. Participates in pastimes/activities to previous standard   [    ] 
 b. Participates but needs instruction/supervision    [    ] 
 c. Reluctant to join in, very slow, needs coaxing     [    ] 
 d. No longer able or willing to join in      [    ] 
 e. Not applicable        [    ] 
 
20. TRANSPORT 
 a. Able to drive, cycle or use public transport independently   [    ] 
 b. Unable to drive but uses public transport or bike etc    [    ] 
 c. Unable to use public transport alone      [    ] 
 d. Unable/unwilling to use transport even when accompanied   [    ] 
 e. Not applicable        [    ] 
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